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I Introduction  
I.1 Quality during the manufacture of pharmaceuticals 
It was rightly said that productivity is driven by the quality of the product (Rochfort Scott, 
Hamerton). Life evolved millions of years ago [1, 2] but the quality of life began to change 
only a few hundred years ago when humans learned to intervene and alter the course of 
diseases. This led to the development of pharmaceuticals approximately 100 years ago, but 
their quality and safety have been improved only since 1960, and this has had an 
unprecedented impact on human life [3, 4]. Even natural products, considered harmless 
because of their origin, initially lacked efficacy and safety during clinical use due to the poor 
production quality [5]. The regulation of vaccines and other biological products has increased 
since the tetanus outbreaks in the early 1900s in the USA, which arose due to the use of a 
contaminated smallpox vaccine and diphtheria antitoxin. This resulted in the Biologic Control 
Act of 1902 followed by the Pure Food and Drug Act in 1906, which launched the Food and 
Drug Administration (FDA) and made it responsible for controlling and authorizing biologics 
before they reached the market. The awareness of pharmaceutical product quality has 
increased since the introduction of current good manufacturing practice (GMP) by the FDA. 
The resulting improvement in quality has several benefits as summarized in Figure I-1. 
 
(Source: http://blog.railsfactory.com/2013/03/the-importance-of-quality-management 
Figure I-1: Impact of quality improvement on related activities.  
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I.2 Biopharmaceuticals  
Plant extracts and purified compounds from plants have been used as medicines for many 
centuries [6, 7] to cure diseases [8, 9] for which written records exist dating back 5000 years 
[10]. This applies to plant proteins such as mistletoe lectins and secondary metabolites such as 
acetylsalicylic acid from the bark of willow trees. Plant metabolites have many therapeutic 
properties, including the ability to treat cancer (e.g. paclitaxel from Taxus brevifolia) [11, 12]. 
Such traditional medicines faced a challenge when the first pure active pharmaceutical 
ingredients (APIs) were developed because it was not possible to clearly define APIs in such 
crude mixtures [8, 13]. The pharmaceutical industry was revolutionized by the development 
of diphtheria antitoxin [14, 15] and antibiotics [16]. Today, pharmaceuticals cover many 
categories of medicine and biopharmaceuticals is a subcategory reserved for peptide APIs that 
may be engineered (changes in sequence, truncations, fusions or secondary modifications) and 
produced in genetically modified organisms (GMOs), to differentiate them from small-
molecules drugs that are not peptides, and which may be extracted directly from their natural 
sources or chemically synthesized [17]. 
The first biopharmaceutical product in the modern sense of the word – recombinant insulin 
produced in Escherichia coli – was approved ~30 years ago [18-21]. Although most such 
products have been manufactured in microbes or mammalian cells, the connection between 
plants and health has re-emerged more recently with botanical therapeutics that contain plant-
derived pharmaceuticals and multicomponent botanical drugs including plant-produced 
recombinant proteins [8]. The estimated global market for phytomedicinal products was US$ 
~60 – 100 billion as reported in 2014 with an average annual growth rate of 7 – 15% [22-24].  
I.3 Plants as production platforms 
The first decades of biopharmaceutical development involved the use of microbial expression 
systems and later mammalian cells. It was not until the 1990s that the potential of plant-based 
expression systems was realized, and interest in such platforms has increased in recent years 
[25, 26] based on the distinct advantages of plants for the production of recombinant proteins 
[27]. Plants have been used to produce industrial enzymes, technical proteins, milk proteins as 
nutritional supplements, and new protein polymers with both medicinal and industrial uses 
[28-31]. Human growth hormone was the first human protein expressed in plants 1986 [32] 
whereas the first complex glycoprotein with multiple subunits was an antibody expressed in 
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plants in 1989 [33]. Many other pharmaceutical proteins have now been successfully 
expressed in plant-based systems (Table I.1).  
 Table I.1 Major pharmaceutical proteins produced in plants [34]. 
Host  plant 
system 
Protein Comments 
Human biopharmaceuticals 
Tobacco, 
sunflower 
Growth hormone 
First human protein expressed in plants, expressed as 
fusion protein with nos. Later expressed in chloroplast, 
~7% total leaf protein [32, 35]  
Tobacco, potato 
Human serum 
albumin 
First native full-size human protein expressed in plants, 
low expression level (0.1% TSP) in transgenic plants 
but 11% in chloroplast [36, 37] 
Rice, turnip α-interferon  
First human pharmaceutical protein expressed in rice 
[38] 
Tobacco  Erythropoietin 
First human pharmaceutical protein expressed in 
tobacco suspension cells [39] 
Tobacco  
Human secreted 
alkaline 
phosphatase 
First human pharmaceutical protein produced by 
secretion from roots and leaves [40, 41] 
Maize  Aprotinin  
First human pharmaceutical protein produced in maize  
[30, 42] 
 
Tobacco  
 
Collagen  
First human structural-protein polymer. Correct 
modification achieved by co-transformation with gene 
encoding modifying enzyme [31, 43] 
Rice  α1-antitrypsin 
First human pharmaceutical protein produced in rice 
cell suspension cultures [44] 
Carrot 
β-
glucocerebrosidase 
First fully regulatory (FDA) approved plant 
pharmaceuticals for human therapeutics [45]  
Recombinant antibodies 
Tobacco  
IgG1 (phosphonate 
ester) 
First antibody expressed in plants (full length serum 
IgG produced by crossing plants expressing heavy and 
light chains) [33] 
Tobacco 
IgM (neuropeptide 
hapten) 
First IgM expressed in plants (chloroplast accumulation) 
[46] 
Tobacco 
SIgA/G 
(Streptococcus 
mutants adhesion) 
First secretory antibody expressed in plants. Sequential 
crossing of four lines carrying individual components 
(most advanced plant-derived pharmaceutical protein at 
present) [47-49] 
Tobacco 
scFv-bryodin1 
immunotoxin (CD 
40) 
First pharmaceutical scFv (and first antibody produced 
in cell suspension cultures) [50] 
Soybean  IgG (HSV) First pharmaceutical protein expressed in soybean [51] 
   
Recombinant subunit vaccines 
Tobacco  
Hepatitis B virus 
envelope protein 
First vaccine candidate expressed in plants, and third 
such candidate in clinical trials [52-55] 
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Maize was used on a commercial basis for the production of enzymes and technical reagents 
including avidin and β-glucuronidase (GUS) by the US-based biotechnology company 
Prodigene Inc. but was limited to diagnostic and research purposes [64, 65]. 
I.4 Economic aspects of plant-made pharmaceuticals (PMPs) 
It is expensive to express recombinant proteins and developing suitable downstream processes  
but several protein expression systems are already established with unique advantages and 
disadvantages [66]. The benefits of plants include the safety profile, because there is low risk 
from human pathogens in seeds and other storage organs [67, 68]. Furthermore, the 
production of recombinant proteins in E. coli is 10–50 times more expensive than in plants 
[69] so plants have economic as well as safety benefits [34, 70]. Similarly, avidin produced in 
maize seeds is approximately 10-fold less expensive to produce than avidin purified from 
eggs using conventional methods [30]. The transient expression of pharmaceutical proteins in 
plants is time saving as well as cost effective [70, 71]. Furthermore, plants can be used to 
produce oral vaccine candidates in seeds, fruits and leaves [70], which need few or no 
downstream processing (DSP) steps, thus reducing production costs dramatically. Economical 
Host  plant 
system 
Protein Comments 
Tomato  
Rabies virus 
glycoprotein 
First ‘oral vaccine’ candidate expressed in plants [56] 
Tobacco, potato 
E. coli heat-labile 
enterotoxin 
First plant-derived vaccine  candidate in clinical trials 
[57, 58] 
Tobacco, potato 
E. coli heat-labile 
enterotoxin 
First plant-derived vaccine  candidate in clinical trials 
[57, 58] 
Tobacco 
Norwalk virus 
capsid protein 
Second plant-derived vaccine  candidate in clinical trials 
[59] 
Tobacco, potato 
Diabetes auto-
antigen 
First plant-derived vaccine candidate for autoimmune 
disease [60] 
Tobacco, potato 
Cholera toxin B 
subunit 
First vaccine candidate expressed in chloroplasts  [61] 
Tobacco 
Cholera toxin B 
and A2 subunits, 
retrovirus 
enterotoxin and 
enterotoxigenic E. 
coli fimbral antigen 
fusions 
First plant-derived multivalent recombinant antigen 
designed for protection against several enteric diseases 
[62] 
Tobacco, maize 
Porcine 
transmissible 
gastroenteritis virus 
glycoprotein S 
Example of first oral feeding inducing protection in an 
animal [63] 
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models based on production costs, product quality and related risks are summarized in Table 
I.2 and Table I.3. 
Table I.2: Production cost effects of different production systems for recombinant human pharmaceutical 
proteins (Lubiniecki AS, Centocor [34]). 
System Overall cost Storage cost 
The manufacture of a monoclonal antibody 
costs ~$200-1000 per gram in cell culture, 
$50 per gram in transgenic animals and $20 
per gram in transgenic plants. 
Bacteria Low Moderate 
Yeast Medium Moderate 
Mammalian cell 
cultures 
High Expensive 
Transgenic 
animals 
High Expensive 
Plant cell culture Medium Moderate 
Transgenic 
plants 
Very low Inexpensive 
 
Table I.3: Comparison of production systems for recombinant human pharmaceutical proteins [34, 72-
74].  
System 
Production 
timescale 
Scale-up 
capacity 
Product 
quality  
Glycosylation 
Contamination 
risks 
Bacteria Short High Low None Endotoxins 
Yeast Medium High Medium Incorrect Low risk 
Mammalian 
cell culture 
Long Very low Very high Correct 
Viruses, prions 
and oncogenic 
DNA 
Transgenic 
animals 
Very long Low Very high Correct 
Viruses, prions 
and oncogenic 
DNA 
Plant cell 
cultures 
Medium Medium High 
Minor 
differences 
Low risk 
Transgenic 
plants 
Long Very high High 
Minor 
differences 
Low risk 
 I. Introduction                                                                                                                  Page 6 
 
Institute for Molecular Biotechnology at the RWTH Aachen University 
PhD thesis 2015 by Zulfaquar Ahmad Arfi 
 
I.5 Quality aspects in the manufacturing of PMPs 
Plants are now widely used to produce biopharmaceutical proteins such as vaccines and 
antibodies [75]. Technical difficulties such as product yield and consistency have been 
addressed, so the major obstacles now relate to clinical development, including GMP 
manufacturing [64, 76, 77]. Initially, the production of biopharmaceutical proteins in plants 
suffered from a lack of regulatory guidance [78]. DSP plays a major role in the regulatory 
processes, which focuses on product quality [64]. The DSP should remove contaminants to a 
level that satisfies the regulators, but in the case of plant-based systems the characteristics of 
these contaminants need to be defined before effective DSP is possible. Plants produce unique 
contaminants that are not found in bacterial and mammalian cell cultures, and the DSP 
operations for bacteria and mammalian systems are designed to remove endotoxins and 
viruses that are not found in plants [64]. However, several organizations including 
SemBioSys Genetics (Calgary, Canada), Kentucky BioProcessing (Owensboro, KY), Icon 
Genetics/Bayer (Halle, Germany), Fraunhofer CMB (Newark, DE), Medicago (Quebec, 
Canada), Fraunhofer IME (Aachen, Germany) have developed GMP processes for the 
extraction of recombinant proteins from plants. 
In May 2012 the first PMP received marketing authorization by US Food and Drug 
Administration (FDA) for human therapeutic use (Elelyso produced by Protalix 
Biotherapeutics, Carmiel, Israel; FDA application number (NDA) 022458) [45], 
demonstrating the economic viability and regulatory compliance of plant-based expression 
platforms.  
I.6 Process-related impurities in PMPs 
Although successful DSP steps have been developed for PMPs there remains a lack of 
experience regarding the removal of host cell proteins (HCPs) during product purification [70, 
79]. The optimization of purification steps can therefore be costly and time-consuming 
because improvements are made by trial-and-error experiments, e.g. screening different 
chromatographic separation conditions. In contrast, if information about the contaminating 
HCPs is available, in silico methods such as quantitative structure–activity relationship 
(QSAR) modeling can be used to predict the optimal separation of HCPs and target proteins 
[70] allowing process development to focus on the most suitable parameters. Poor 
understanding of HCP contaminants can also lead to regulatory concerns during the approval 
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process because HCPs form part of the process-related impurities and can hence be regarded 
as a safety risk if present in the final product [64, 80, 81].  
I.7 HCP quantification 
The production of biopharmaceutical proteins in plants and other systems produces a 
spectrum of process-related contaminants that may include HCPs and nucleic acids, media 
components, bacterial endotoxins, viruses, metabolites and cell debris, all of which must be 
removed from the feed stream [82, 83]. The successful removal of these contaminants must be 
validated using appropriate assays to satisfy GMP requirements [84, 85]. Tobacco is one of 
the most advanced platforms for the production of PMPs and is suitable for both stable 
expression (transgenic plants) and transient expression by agroinfiltration and/or the use of 
viral vectors [34, 66]. The feed stream for downstream processing may therefore contain 
tobacco-specific HCPs, nucleic acids, fibers and oils, and also endotoxins from plant-
colonizing bacteria, particularly when proteins are produced by transient expression using the 
agroinfiltration method [86]. 
HCPs are the major process-related impurities in filtered extracts of plants [87]. The presence 
of residual HCPs in the final API has the potential to cause toxicity or immunogenicity and 
these contaminants must therefore be reduced to acceptable and safe levels [88-90]. During 
the production of biopharmaceutical proteins, a limited number of DSP steps such as filtration 
and chromatography are used to isolate target proteins from the primary extract, which 
essentially contains the host plant proteome as process impurities. If applicable, a selective 
early DSP step is used to enrich the product. However, even affinity chromatography fails to 
completely remove all HCPs from the feed stream [91], because they may bind to the product 
or to the resin. Residual HCP levels must be quantified to satisfy GMP regulations, so 
quantitative assays are needed to detect HCPs [83].  
Methods such as one dimensional (1-D) and two dimensional (2-D) polyacrylamide gel 
electrophoresis (PAGE) followed by silver staining are generally used to detect proteins but 
may fail to differentiate between process-related and product-related impurities. Also, this 
method is less sensitive than immunoassays, which detect as little as 1 ng mL-1 protein [92]. 
Therefore, the development of a multi-analyte immunoassay would be the preferred approach 
for HCP detection and is more likely to be accepted by the regulatory bodies [83]. This can be 
accomplished by raising HCP-specific antibodies against the components of the expression 
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system without a recombinant protein product. It would then be possible to state that HCPs in 
the API are below the detection level of a sensitive assay [93]. The regulatory bodies demand 
that residual DNA should be reduced to levels no higher than 100 pg per therapeutic dose, but 
there is no set limit for HCPs. This is considered on a case-by-case basis depending on the 
API, route of administration, dose frequency and other parameters [94], although an FDA 
review recommends that HCPs not exceed 100 ppm in the final product [88, 95].  
I.8 HCP immunoassays 
The early development of an HCP immunoassay would be beneficial because process 
validation is a long process and the availability of an assay saves time during regulatory filing 
for initial clearance [96]. The assay not only allows the detection of impurities in the API, but 
also allows then to be traced during process development thus simplifying the final DSP 
scheme and making production less expensive. 
E. coli and Chinese hamster ovary (CHO) cells are established biopharmaceutical platforms 
and commercial HCP assays are available [97]. For plant-based production platforms, it 
remains necessary to develop specific in-house assays for each host [83, 92, 95]. Fraunhofer 
IME works with tobacco-based production systems and there are no commercially-available 
immunoassays with the range and sensitivity available to detect a representative spectrum of 
tobacco HCPs. It is therefore necessary to develop a tobacco HCP immunoassay for the 
production of PMPs using this platform.  
I.9 Development of anti-HCP antibodies  
The most suitable animals for immunization with HCPs are determined by the amount of 
antisera required and the strength of the immune response [83]. Rabbits are often used for the 
generation of polyclonal antibodies but goats are preferred when larger amounts or antisera 
are required. The greater the phylogenetic distance between animal and antigen, the better the 
immune response, although this is not such an important criterion when the antigens are 
derived from plants [98]. However, the other major concern during the development of 
polyclonal antibodies is the effect of superabundant proteins present in the protein mixture, 
because these may suppress the immune response against scarcer proteins by antigen 
competition [83, 99, 100].  
Developing antibodies against the wide range of tobacco HCPs is therefore challenging due to 
the presence of ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO), a 
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superabundant protein that can cause immunogenic suppression [101]. RuBisCO accounts for 
30–50% of total soluble protein (TSP) in the green tissues of plants [102] and it is therefore 
important to deplete plant extracts of this protein in order to generate antibodies against a 
wider range of HCPs. 
Before injecting HCPs into the animals, it is also important to ensure that endotoxins are 
removed. Gram-negative bacteria produce endotoxins known as lipopolysaccharides (LPS) 
that accumulate in the outer membrane [103-105] and cause toxic effects when injected into 
the animals, even at concentration of 1–2 ng mL-1 [106]. Endotoxins act indirectly by 
triggering an immune response that can result in fatal septic shock [107]. Although plants do 
not produce endotoxins, they may be present in plant extracts due to the presence of bacteria 
colonizing the plant surface or plant tissues. 
Therefore special care is required for to remove or reduce the levels of RuBisCO and 
endotoxins before immunization. This combination of methods should therefore allow the 
development of polyclonal antibodies over a wide range of HCPs, so that a suitable antibody 
panel can be developed for the detection of HCPs during the purification of PMPs. 
I.10 Opportunities for immunoassay development 
Immunoassays have played a significant role in pharmaceutical development since their 
conception and are now used to control the quality of commercial pharmaceuticals and DSP 
development. Immunoassays play significant role in regulatory compliance and clearance. 
The big players in immunoassay development and marketing are Abbott laboratories (US), 
Alere Inc. (.S), Danaher Corporation (US), Roche Diagnostics (Switzerland), Siemens 
Healthcare (Germany) and Sysmex Corporation (Japan). The global market for immunoassays 
is worth ~US$ 13.0 billion and is expected to reach US$ 19.1 billion by 2018 with a 
compound annual growth rate of 8.1%.   
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I.11 Aim of the thesis and workflow   
Fraunhofer IME has pioneered the development of biopharmaceuticals using plant-based 
expression systems, including transient expression in tobacco, transgenic tobacco plants and 
plant suspension cell cultures. The important role of HCPs in quality control are stated above 
(sections I.6 and I.7) highlighting the need to develop an immunoassay for tobacco HCPs. 
Polyclonal antibodies were therefore raised against HCPs from wild-type lines of the tobacco 
species N. tabacum (used to produce transgenic plants) and  N. benthamiana (which is 
agroinfiltrated with the bacterium Agrobacterium tumefaciens for transient expression). The 
work described in this thesis focuses on the development of antibodies against a wide range of 
antigens, which requires efficient RuBisCO depletion and endotoxin removal (section I.8). A 
generic immunoassay was thus established to detect a wide range of HCPs against both 
tobacco species, and the antibodies were characterized by western blot and enzyme-linked 
immunosorbent assay (ELISA) procedures. Finally, the generic immunoassay was tested for 
its ability to detect HCPs during the production of several model recombinant proteins in 
tobacco. The work flow described in this thesis is summarized in Figure I-2.  
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Figure I-2: Workflow carried out during this PhD project. 
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II Methods  
II.1 Equipment 
All equipment is listed in the appendix, section VII.1. All chemicals and buffers are listed in 
the appendix, sections VII.2 and VII.3 respectively. 
II.2 Plant species and growth 
Wild-type N. tabacum (SR1), wild-type N. tabacum (K326), wild-type N. benthamiana and 
agroinfiltrated N. benthamiana were used for antigen preparation. 
Tobacco plants were grown under controlled conditions at the Fraunhofer IME greenhouse 
facility, Aachen, Germany, under the supervision of Dr. Thomas Rademacher. Rock wool 
blocks (Cultilene, Netherlands) or earth units Type T1.5 were used for the germination of 
tobacco seeds. Plants were grown in a greenhouse (25/22°C day/night temperature, 70% 
relative humidity and a photoperiod of 16 h provided by Philips Son-T GreenPower 600 W 
high pressure sodium lamps). A 0.1% (w/v) solution of Ferty 2 Mega (Kammlott GmbH, 
Germany) was used for irrigation. N. tabacum plants were harvested 7 weeks after seeding. N. 
benthamiana plants were taken for infiltration after 6 weeks of growth and transferred to 
hydroponic solution in stone wool blocks in a phytotron (25/22oC day/night temperature, 70% 
relative humidity and a photoperiod of 16 h provided by Philips GreenPower DR/B 120 
LEDs). Ferty 2 Mega (0.05–0.015% w/v) was used for irrigation. 
II.3 Bacterial growth and tobacco infiltration 
Bacteria (A. tumefaciens GV3101:pMP90RK) were grown in yeast extract broth (YEB) (Table 
II.1) supplemented with 50 µg mL-1 carbenicillin, 25 µg mL-1 kanamycin and 25 µg mL-1 
rifampicin for selection. The culture was incubated at 25°C shaking at 160 revolutions per 
minute (rpm) for 72 h in the presence of 40 µg L-1antifoam (Struktol J673) to avoid frothing.  
Table II.1: YEB medium 
Component Concentration [%] (w/v) 
Yeast extract 0.1 
Beef extract 0.5 
Peptone 0.5 
Magnesium sulfate 0.05 
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A. tumefaciens were cultured to an optical density of OD600nm = 5 and diluted with twofold 
infiltration medium (0.1% (w/v) sucrose, 0.36% (w/v) glucose, 0.86% (w/v) Murashige and 
Skoog salts, 0.4 mM acetosyringone) and purified water to OD600nm = 1.0. Bacteria were 
injected into the plant (N. benthamiana, 6 weeks old) either manually using a 1-mL syringe or 
by vacuum infiltration at 20 mbar for 10 min followed by vacuum release. 
The infiltrated plants were incubated for 4 days in a phytotron as above using Osram cool 
white 36 W fluorescent tubes. The infiltrated plants were harvested 5 days post-injection (7 
weeks post-seeding).  
II.4 Isolation of total proteins from tobacco plants 
Proteins were extracted from wild-type N. tabacum (SR1), N. tabacum (K326) and 
agroinfiltrated N. benthamiana in three volumes (w/v) of extraction buffer (50 mM disodium 
phosphate, 10 mM sodium sulfate, 250 mM sodium chloride, pH 8.0) in a commercial blender 
(Warring, CT, USA). The extract was filtered through Miracloth 1R (Merck, Germany) and 
centrifuged (Avanti J-26 XP, Beckman coulter, USA) twice at 16,000 x g, 20 min, 4oC. The 
supernatant was filtered through a Sartopore 2 150 disposable capsule filter (0.45 + 0.2 µm) 
module (Sartorius-Stedim, Goettingen, Germany). 
II.5 Protein quantification    
Samples collected at each step were analyzed using the Bradford method [108, 109] to 
determine the quantity of total soluble protein (TSP). A 200-µL aliquot of Bradford reagent 
(Thermo Fisher Scientific, Rockford, Illinois, USA) was mixed with 2.5 or 5.0 µL extract in a 
96-well plate and absorbance was measured at 595 nm using a synergy HT plate reader 
(BioTek Instruments, Winooski, Vermont) after 10 min incubation at room temperature (RT). 
Bovine serum albumin (BSA) in eight dilutions [0–2000 µg mL-1] was measured in triplicate 
to establish a standard curve which was used to calculate the unknown sample concentrations. 
Samples with very low protein concentrations were quantified using the Lowry test [110-112]. 
A 40-µL sample (or BSA or antibody standard, 0–2000 µg mL-1) was mixed with 200 µL 
Lowry reagents and incubated at RT for 10 min. Then 20 µL of Folin reagent was added and 
incubated for 30 min at RT and absorbance was measured at 700 nm as above. The plotted 
standard curve was used to calculate the unknown sample concentrations. 
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Antibody quantities were calculated by surface plasmon resonance (SPR) spectroscopy using 
a Biacore T200 instrument (GE Healthcare, Uppsala, Sweden) to measure the binding of the 
antibody to Protein A (Sigma–Aldrich, St. Louis, MO, USA) immobilized on the surface of a 
CM5 chip by EDC/NHS coupling [113-115]. A reference (500 µg mL-1) was used for 
one-point calibration with HBS-EP as the running buffer. The antibody concentrations were 
also estimated by the Bradford and Lowry methods and by size exclusion chromatography 
(SEC).  
II.6 RuBisCO depletion 
 RuBisCO depletion using sodium phytate 
RuBisCO was depleted by precipitation with sodium phytate (Sigma–Aldrich, Steinheim, 
Germany) and calcium chloride [116]. The filtered extract (N. tabacum SR1) was mixed with 
5 mM or 10 mM sodium phytate-calcium chloride and incubated at 42°C for 10 min before 
centrifugation (16,000 x g, 10 min, 4°C). The supernatants were collected and the pellets were 
re-dissolved in buffer (50 mM sodium phosphate, 150 mM sodium chloride, pH 7.5) for 
further analysis. 
 RuBisCO depletion using polyethylene glycol (PEG) 
RuBisCO depletion by PEG [117-121] was achieved by dividing the filtered plant extract into 
two portions, one of which was dialyzed against phosphate buffer (pH 6.5) without additional 
sodium chloride. The original and desalted extracts were then each mixed with 12%, 14%, 
15% or 16% (w/v) PEG 4000 (Applichem Darmstadt, Germany) and incubated on ice for 30 
min. The original extracts and the desalted extracts were centrifuged at 16,000 x g for 20 min 
at 4°C. The supernatant was collected and the precipitate was solubilized in buffer (50 mM 
sodium phosphate, 150 mM sodium chloride, pH 7.5) for further analysis.  
II.7 Ultrafiltration/diafiltration (UF/DF) 
UF/DF was used for buffer exchange [122]. Different molecular weight cut off (MWCO) 
membranes, i.e. 3 kDa (Pall Life Sciences, NY, USA), 10 kDa and 30 kDa (Sartorius-Stedim), 
500 kDa and 1000 kDa (Millipore, MA, USA) were used depending on the size of the target 
proteins. A feed pump was used to pump proteins into the membrane, and those with higher 
molecular weights than the membrane MWCO were retained while smaller proteins passed 
through into the permeate. The UF/DF systems were washed as recommended according to 
the manufacturer’s instructions. The initial volume was reduced by 10-fold and then two 
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volumes of dialysis buffer was added and the volume was again reduced to half. This was 
carried out five times. The UF/DF system was washed according to the manufacturer’s 
instructions and stored in 20% (v/v) ethanol or as instructed in the manual. 
II.8 Endotoxin depletion/removal 
 Endotoxin removal using Polymyxin B agarose 
Polymyxin B agarose has affinity for endotoxins [123-125]. The plant extract was dialyzed by 
UF/DF (section II.7) against loading buffer (50 mM sodium phosphate, 100 mM sodium 
chloride, pH 7.5) and injected into a PD10 column (Pharmacia Biotech, Uppsala, Sweden) 
pre-packed with 1 mL or 4 mL Polymyxin B agarose (Sigma–Aldrich) that had been washed 
with 10 column volumes (CV) of water and equilibrated with 10 CV of loading buffer. After 
washing with 5 CV of the loading buffer, the flow-through fraction was collected and the 
column was regenerated and stored according to the manufacturer’s instructions. The flow 
through fraction was tested using either the Lonza endotoxin kit or the Charles River endosafe 
kit. 
 Endotoxin removal using EndoTrap blue 
EndoTrap blue (Hyglos GmbH, Germany) was used for endotoxin depletion/removal. The 
plant extract was dialyzed by UF/DF (section II.7) against loading buffer (20 mM HEPES 
buffer, 0.1 mM calcium chloride and 150 mM sodium chloride, pH 7.5) and the extract was 
passed through a 1-mL EndoTrap blue column pre-equilibrated with 10 CV of the loading 
buffer. After washing with 5 CV of loading buffer, the flow through was collected and the 
column was regenerated and stored according to the manufacturer’s instructions. The 
flow-through fraction was tested using the kits described above. 
 Endotoxin depletion using FiberFlo EN filters 
FiberFlo EN filters (Zind Verfahrenstechnik, Mainz, Germany) were cleaned with water and 
equilibrated with sample buffer (as required during the procedure). The filtered plant extract 
was passed through the filter three times. After each pass, the filter was washed thoroughly 
with sample buffer to recover the proteins and then sanitized with 1 M sodium hydroxide to 
remove the bound endotoxin before re-equilibration with sample buffer. The collected 
flow-through fractions were analyzed.  
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The endotoxin depletion/removal process for tobacco HCPs is summarized in Figure II-1. 
 
Figure II-1: Endotoxin removal/depletion strategies for different tobacco extracts. 
II.9 One-dimensional LDS-PAGE analysis 
One-dimensional lithium dodecylsulfate polyacrylamide gel electrophoresis (1-D LDS-
PAGE) was carried out using pre-cast Bis-Tris 4–12% gels (Life Technologies) with samples, 
gels and equipment prepared according to the manufacturer’s protocol [126, 127]. The protein 
samples were boiled for 10 min at 70°C in LDS-sample buffer and reducing agent and 10-µL 
samples were loaded and separated for 40 min at a constant 200 V in MES buffer. The gels 
were washed in water for 5 min and then stained with SimplyBlue SafeStain (detection limit = 
7 ng) [128, 129] for at least 1 h followed by washing with water to remove surplus stain. The 
washed gels were then scanned with a Canon 8800 (Canon, Krefeld, Germany) at 600 dpi and 
saved as Adobe Photoshop 6.0 files (San Jose, CA, USA). The Life Technologies SilverQuest 
kit (detection limit = 3 ng) [130, 131] was used for silver staining according to the 
manufacturer’s instructions. 
II.10 Two-dimensional SDS-PAGE analysis 
Two-dimensional sodium dodecylsulfate polyacrylamide gel electrophoresis (2-D SDS-
PAGE) [132] was carried out by dialyzing protein extracts against sodium phosphate buffer 
(pH 8.0) to remove salts and concentrate the TSP to 20 mg mL-1. The processed samples were 
passed through a 0.2-µm filter and used immediately or stored at –80°C. When the sample is 
highly concentrated, a stronger rehydration buffer can be used (7 M urea, 2 M thiourea, 4% 
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(w/v) CHAPS, 30 mM Tris, pH 8.8) which prevent water loss. Prior to isoelectric focusing 
(IEF), the samples were prepared as shown in Table II.2.  
Table II.2: Sample preparation for 2-D gel electrophoresis (IEF gel) 
Gel strips 7 cm 18 cm 
Volume per strip (µL) 
(at least 75% rehydration buffer) 
125 300 
Protein load (µg) 
(pH 4–7) 
400 1000 
2.5 M DTT (µL) [40 mM] 
100% pharmalytes (µL) [1%] 
Bromophenol blue (BPB) 
2.0 
1.25 
1 drop 
4.8 
3 
1 drop 
  
The samples were centrifuged for 10 s at 1200 x g to remove insoluble particles and the IEF 
electrophoretic chamber (7 cm or 18 cm) was placed in the PROTEAN IEF cell (Bio-Rad, 
MA, USA). The samples were pipetted into the electrophoretic chambers and then placed on 
the pH 4–7 IEF strips (Bio-Rad, MA, USA). A small amount of oil was applied to remove the 
bubbles and the lid was fitted before rehydration in rehydration buffer for 10–12 h. After 
rehydration, IEF was started as shown in Table II.3 using a Protean IEF (Bio-Rad, MA, USA) 
with a current limit of 50 µA per strip. 
Table II.3: IEF program depending on the size of the gel strip 
Steps 
Volts Time (h:min) 
7 cm 18 cm 7 cm 18 cm 
S1 300 500 3:00 1:00 
S2 1000 1000 0:30 8:00 
S3 5000 8000 1:30 3:00 
S4 5000 8000 3:00 (till end) 6:00 (till end) 
     
The strips were equilibrated in equilibration buffer (6 M urea, 30% (w/v) glycerol, 2% (w/v) 
SDS, 50 mM Tris, pH 8.8) containing 1% (w/v) dithiothreitol (DTT)) for 15 min followed by 
equilibration with same buffer containing 2.5% (w/v) iodoacetamide (IAM) for 15 min.  
Second-dimension separation was carried out using 7-cm or 18-cm SDS-polyacrylamide gels 
(12% (w/v) polyacrylamide). The 7-cm gels were run at 80 V for 10 min and then 200 V for 
1.5 h, whereas the 18-cm gels were run at 80 V for 15 min and then 200 V for 4.5 h. The gels 
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were stained depending on requirements with SimplyBlue SafeStain, the SilverQuest kit or 
SYPRO Ruby (Thermo Fisher Scientific) [133, 134] according to the manufacturers’ 
instructions. 
II.11 Mass spectrometry (MS) 
The protein bands from 1-D LDS-PAGE (section II.9) or protein spots from 2-D SDS-PAGE 
(section II.10) were identified by MS [135, 136]. After washing the gel, the selected area 
containing the protein was removed with a clean scalpel. The proteins were reduced in 10 mM 
DTT and alkylated with at least 55 mM IAM (both prepared in 100 mM sodium bicarbonate 
buffer). The proteins were digested with trypsin [137], extracted in 5% (v/v) formic acid in 25 
mM ammonium buffer and identified by MS [138] using Mascot v2.3.01 (Matrix Science Ltd, 
London) to search the NCBInr or SWISS-Prot or Nicotiana benthamiana databases. MS 
analysis was performed by Dr. Ivana Chudobova (Fraunhofer IME, Aachen). 
II.12 Immunization (generation of polyclonal antibodies) 
N. tabacum, N. tabacum (RuBisCO-depleted) and N. benthamiana HCPs (NtHCP, NtRdHCP 
and NbHCP) were used for immunization after endotoxin removal and sterile filtration. 
Rabbits and goats were immunized with HCPs in BioGenes Adjuvant by BioGenes GmbH, 
Berlin (Germany). Immunization and bleeding were carried out as shown in Table II.4. 
Table II.4: Immunization and bleeding for the generation of polyclonal antibodies against tobacco HCPs. 
Days Immunization/bleeding 
0 Bleeding (pre-immune) and immunization 1 
14 Immunization 2 
28 Immunization 3 
42 Immunization 4 and bleeding  
56 Immunization 5 
63 Bleeding 
77 Immunization 6 
84 Bleeding 
98 Immunization 7 
105 Bleeding 
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II.13 Purification of anti-HCP antibodies  
The anti-HCPs antibodies from rabbits (section II.12) were purified using MabSelect SuRe 
Protein A (GE Healthcare) and the anti-HCPs antibodies from goats were purified using 
Protein G Sepharose (GE Healthcare). Sera from the third, fourth and fifth bleeds from rabbits 
injected with processed NtHCP, NtRdHCP and NbHCP were pooled and diluted 1:5 with 
loading buffer (20 mM sodium phosphate,150 mM sodium chloride, pH 7.2 for Protein A; 20 
mM sodium phosphate, pH 7.0 for Protein G). The solutions were passed through a 0.2-µm 
filter before loading on to a pre-equilibrated Protein A or Protein G column (loading protein 
amount was 70% of resin capacity). The column was washed with loading buffer until the OD 
returned to base level. Antibodies were eluted with 100 mM glycine/HCl buffer (pH 3.0) and 
the elution fraction was neutralized with 1 M Tris buffer (pH 8.5). 
II.14 One-dimensional western blot 
Proteins were transferred to a nitrocellulose membrane (GE Healthcare, Waukesha, WI, USA 
and Life Technologies, MA, USA) after separating them on 1-D LDS-PAGE (section II.9) at 
constant 30 V for 1 h using blotting chamber from Life Technologies. The proteins were 
incubated with anti-HCPs antibodies after blocking with 3% (w/v) BSA in phosphate-buffered 
saline (PBS) containing 0.05% (v/v) Tween-20 (PBS-T). The secondary antibody, conjugated 
to alkaline phosphatase (AP), was detected with nitroblue tetrazolium (NBT) and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP). NBT and BCIP solution (stock mixtures 0.3 and 0.15 mg 
mL-1 respectively) were diluted 1:100 in AP buffer (100 mM Tris, 100 mM NaCl, 5 mM 
MgCl2, pH 9.6). 
II.15 Two-dimensional (2-D) western blot 
Proteins were transferred to a nitrocellulose membrane as above after separation by 2-D SDS-
PAGE (section II.10) at constant 30 V for 1 h (7-cm gel) or 6 h (17-cm gel) using a Bio-Rad 
blotting chamber. The proteins were incubated with anti-HCPs antibodies after blocking as 
above and detected using the secondary antibody and colorimetric reagents described above. 
II.16 Image analysis 
Advanced image data analyzer (AIDA) v4.27.039 (Raytest Isotopenmessgrate GmbH,  
Straubenhardt, Germany) was used to monitor RuBisCO depletion by comparing the 
RuBisCO spot areas (intensity/width) in PEG-precipitated and untreated samples separated by 
2D SDS-PAGE. After scanning 2-D silver-stained gels and 2-D western blots at 600 dpi with 
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a Canon 8800, the protein spots were analyzed using the Delta2D image analysis software 
(Decodon, Greifswald, Germany). The images were imported into the software and warped 
together forming a master image. The spots were detected and quantified according to their 
brightness intensity with the local background radius set to 32 pixels, an average spot radius 
of 10 pixels and a spot detection sensitivity of 20. Artifacts such as dust and scratches that are 
characterized by a steep slope at the object edges in a 3D intensity plot were manually 
removed. 
II.17 Enzyme linked immunosorbent assay (ELISA) 
Different ELISA variants (direct ELISA, indirect ELISA and sandwich ELISA) [139] were 
used for the qualitative and quantitative analysis of proteins as appropriate.  
  Direct and indirect ELISA 
The samples (antigens) and standards (tobacco HCPs) (2.5–100 ng∙mL-1) were coated (100 µL 
per well) in coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6) 
and incubated overnight at 4°C. All further steps were carried out at RT. The free binding sites 
were blocked with 3% (w/v) BSA in PBS-T (250 µL per well) for 1 h. The anti-HCP 
antibodies conjugated to horseradish peroxidase (HRP) were diluted 1:500 in PBS and 
incubated for 1 h at RT (100 µL per well). Unlabeled anti-HCP antibodies were detected 
indirectly using a secondary IgG-specific antibody (diluted 1:5000) conjugated to AP or HRP 
and detected with ABTS or phosphatase substrate by measuring absorbance at 405 nm after 
20–30 min for direct ELISA and 5–10 min for indirect ELISA. The plotted standard curve 
was used to quantify the concentration of unknown samples. All washing step were carried 
out three times (250 µL per well) between steps with 0.5% (w/v) BSA in PBS-T.  
 II. Materials and methods                                                                                                Page 21 
 
Institute for Molecular Biotechnology at the RWTH Aachen University 
PhD thesis 2015 by Zulfaquar Ahmad Arfi 
 
  Sandwich ELISA 
The capture antibody (goat anti-HCP) was coated (100 µL per well) in coating buffer and 
incubated overnight at 4oC. The free binding sites were blocked with 3% (w/v) BSA in PBS-T 
(250 µL per well) for 1 h. The tobacco HCP samples (100 µL per well) were incubated for 2 h 
at RT. The detection antibody (rabbit anti-HCP) conjugated with HRP (100 µL per well) were 
incubated for 1 h at RT. The unlabeled detection antibody was quantified using the secondary 
IgG-specific antibody (diluted 1:5000) conjugated to AP or HRP as described in section 
II.17.1.  
  Checker board titration 
Checker board titration is used to optimize concentrations of antigens–antibodies and 
antibodies–antibodies [140]. The following two models were adapted to optimize each ELISA 
setup, to study the cross-reactivity between antibodies and to find combinations showing 
minimum cross reactivity or no cross reactivity. 
Model 1   
 
                                                      
                                                          
Black: Coating antibody µg mL-1  
Red: Detection antibody HRP (dilutions) 
1-4: Column name 
A-D: Row name                                                       
 
 
 
1 2 3 4 
 
A 
4 
1:2000 
2 
1:2000 
1 
1:2000 
0.5 
1:2000 
 
B 
4 
1:4000 
2 
1:4000 
1 
1:4000 
0.5 
1:4000 
 
C 
4 
1:8000 
2 
1:8000 
1 
1:8000 
0.5 
1:8000 
 
D 
4 
1:16000 
2 
1:16000 
1 
1:16000 
0.5 
1:16000 
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Model 2   
 
 
1 2 3 4 5 6 7 8 9 
 
A 
4 
50 
4 
1:5000 
4 
10 
4 
1:5000 
4 
0 
4 
1:5000 
2 
50 
4 
1:5000 
2 
10 
4 
1:5000 
2 
0 
4 
1:5000 
1 
50 
4 
1:5000 
1 
10 
4 
1:5000 
1 
0 
4 
1:5000 
 
B 
4 
50 
2 
1:5000 
4 
10 
2 
1:5000 
4 
0 
2 
1:5000 
2 
50 
2 
1:5000 
2 
10 
2 
1:5000 
2 
0 
2 
1:5000 
1 
50 
2 
1:5000 
1 
0 
2 
1:5000 
1 
0 
2 
1:5000 
 
C 
4 
50 
2 
1:5000 
4 
10 
2 
1:5000 
4 
0 
2 
1:5000 
2 
50 
2 
1:5000 
2 
10 
2 
1:5000 
2 
0 
2 
1:5000 
1 
50 
2 
1:5000 
1 
10 
2 
1:5000 
1 
0 
2 
1:5000 
 
D 
4 
50 
1 
1:5000 
4 
10 
1 
1:5000 
4 
0 
1 
1:5000 
2 
50 
1 
1:5000 
2 
10 
1 
1:5000 
2 
0 
1 
1:5000 
1 
50 
1 
1:5000 
 
1 
10 
1 
1:5000 
 
1 
0 
1 
1:5000 
Black: Coating antibody (µg∙mL-1)  Green: Second antibody (µg∙mL-1) 
Blue: Antigen (ng∙mL-1)    Red:   Detection antibody (dilutions) 
1-9: Column name   A-D: Row name                                                       
II.18 Antibody labeling 
Anti-HCP antibodies used for detection were labeled with HRP [94, 141, 142] using 1 mg EZ-
Link Plus Activated Peroxidase (Thermo Fisher Scientific) reconstituted with 1 mg of anti-
HCP antibodies prepared in 1 mL PBS (pH 7.2) according to the manufacturer’s instructions. 
This was immediately mixed with 10 µL sodium cyanoborohydride in a laminar hood and 
incubated at RT for 1 h before quenching and incubating for a further 15 min at RT. The non-
conjugated enzymes were removed from the mixture by SEC and the labeled antibody was 
stored briefly at 4°C or for longer at –20°C in 50% (v/v) glycerol.   
II.19 Protein coupling 
Proteins can be coupled to Sepharose to establish affinity matrices [143, 144] for protein 
purification and to eliminate cross-reactive molecules [94]. The antibodies and HCP antigens 
described in this project were coupled to NHS-activated Sepharose-4 fast flow (mean particle 
size = 90 µm, particle size range = 45–165 µm, spherical highly cross-linked 4% agarose) 
(GE Healthcare) according to the manufacturer’s instructions. The coupling solutions were 
prepared in coupling buffer (200 mM sodium bicarbonate, 500 mM sodium chloride, pH 8.3). 
The NHS-activated Sepharose-4 fast flow was washed with cold 1 mM HCl in 10-15 medium 
or matrix volume before use. The coupling solution and washing buffer were mixed and the 
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pH was adjusted (pH 8.3). The coupling was carried out at RT for 4 h or overnight at 4°C. 
Any non-reacted groups in the medium were blocked with 100 mM Tris-HCl (pH 8.5) for 2–3 
h (or at 4°C overnight). After blocking, coupled matrices were washed 3–6 times with two 
alternating buffers varying in pH (100 mM Tris-HCl. pH 8.5 and 100 mM acetate buffer, 500 
mM sodium chloride, pH 4.0). The affinity-coupled matrix was stored in 20% (v/v) ethanol to 
prevent microbial contamination. 
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III Results and discussion 
The results presented in the result section are part of the following publication 
1. Polyclonal antibodies specifically detecting tobacco host cell proteins can effectively 
be generated after RuBisCO depletion and endotoxin removal. Arfi et al., 
Biotechnology Journal (submitted) – Sections III.1 and III.2.  
 
2. A subset of tobacco host cell proteins binds to Protein A resin during purification of 
monoclonal antibodies. Arfi et al., Plant Biotechnology Journal (in preparation) – 
Section III.6.1. 
 
III.1  Antigen preparation (N. tabacum SR1 and N. benthamiana) 
 Isolation of HCPs from tobacco plants 
Total soluble protein (TSP) was extracted from wild-type N. tabacum (SR1) and N. 
benthamiana plants [145] for the immunization of animals (rabbits or goats). After 
centrifugation, sterile filtration was used for particle removal and UF/DF was used for buffer 
exchange (Section II.7). 
The initial yields per gram of plant biomass were 6.15 ± 0.23 mg for N. tabacum and 5.69 ± 
0.24 mg for N. benthamiana (n = 3 for both species) (Figure III-1B). A small amount of TSP 
was lost during purification by centrifugation and UF/DF, resulting in recoveries of 92 ± 5% 
for N. tabacum and 90 ± 2% for N. benthamiana (n = 3 for both species). LDS-PAGE  
followed by staining with Coomassie Brilliant Blue revealed two dominant protein bands in 
each extract (~50 kDa and ~15 kDa) matching the anticipated sizes of the large and small 
RuBisCO subunits [146]. No proteins were detected in the 5-kDa membrane permeate (Figure 
III-1A) confirming the complete retention of proteins during this step. A 5-kDa MWCO 
membrane was used for buffer exchange to avoid protein loss from the samples [122, 147]. 
This was important to ensure the presence of a complete host cell proteome during the 
subsequent immunization. HCP levels were determined using the Bradford method with BSA 
as a standard. 
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Figure III-1: Extraction of HCPs and RuBisCO depletion. A. LDS-PAGE (section II.9) followed by 
Coomassie staining showed that HCPs from N. tabacum and N. benthamiana were the same after centrifugation 
(1), subsequent filtration (2) and remained in the 5-kDa membrane retentate (3) with the RuBisCO large (~53 
kDa) and small (~14 kDa) subunits as dominant bands. No HCPs were found in the 5-kDa membrane permeate 
(4). M – Molecular mass marker. B. TSP concentrations in extract process samples of N. tabacum and N. 
benthamiana were determined according using the Bradford method. The remaining amount of RuBisCO after 
PEG precipitation (section II.6.2) was calculated based on densitometric analysis (B). Error bars indicate 
standard deviations (n ≥ 3). 
 Depletion of RuBisCO (N. tabacum) 
RuBisCO accounts for 30–50% of TSP isolated from green plant tissues [102]. The presence 
of highly abundant proteins in a HCP mixture can cause antigenic competition resulting in a 
weak immune response against less abundant proteins [83, 92]. In order to overcome this 
effect and obtain antibodies against the majority of HCPs, it was necessary to reduce the 
amount of RuBisCO relative to other HCPs before immunizing animals (rabbits or goats). 
RuBisCO depletion can be achieved by affinity-based depletion methods [148], sucrose 
density-gradient centrifugation [149] and anion-exchange chromatography [150], but these 
methods are expensive, time consuming and expensive [148, 151-155]. Therefore, two cost-
effective strategies for RuBisCO depletion were tested – calcium chloride/sodium phytate 
precipitation [116, 156] and PEG precipitation [117, 120] – in each case aiming for ~70–80% 
depletion. 
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In the PEG method [117], the filtered and clarified green juice was mixed with the 
precipitation reagent resulting in the selective precipitation of RuBisCO with minimal impact 
on other HCPs. Approximately 70‒92% of total RuBisCO precipitated in the presence of 12‒
16% (w/v) PEG (Figure III-2A), allowing the precipitate to be removed by centrifugation .The 
amount of TSP in the supernatant following RuBisCO depletion declined with increasing 
concentrations PEG, and greater amounts of RuBisCO were found in the precipitate (Figure 
III-1B and Figure III-2A). In the most efficient example of this method, 92% RuBisCO 
depletion was achieved with 16% (w/v) PEG, in good agreement with published data 
reporting >90% reduction with 16% (w/v) PEG [117]. 
 
Figure III-2: RuBisCO depletion (section II.6.2) from N. tabacum extracts. A. Protein bands found in N. 
tabacum homogenates (H), supernatants (S) and precipitates (P) after the addition of PEG at various 
concentrations. High PEG concentrations and desalting caused additional proteins to precipitate (green and red 
arrows, respectively). Ds – Desalted samples; M – Molecular mass marker. B. Densitometric analysis of protein 
samples after LDS-PAGE and Coomassie staining. 
Also, the effect of PEG precipitation on other proteins during RuBisCO depletion was 
investigated. Increasing the PEG concentration from 14% (w/v) to 16% (w/v) reduced the 
abundance of HCPs with molecular masses of 115, 70 and 40 kDa (Figure 1B, green arrows) 
by 1.3 ± 0.2, 1.4 ± 0.1 and 1.0 ± 0.7 fold, respectively (n = 4, Figure III-2B, green arrows). 
Protein analysis by MS revealed 22 additional HCPs in the RuBisCO-depleted extract that 
were not detected in the presence of high quantities of RuBisCO (Table III.1) while at the 
same time 8 proteins were not detected in the RuBisCO-depleted extract (marked in red Table 
III.1). A complete list of proteins detected in the RuBisCO-depleted and non-depleted extracts 
is provided in Supplementary Table VII.1. The impact of desalting on the recovery of HCPs 
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was also evaluated using a 5-kDa UF/DF membrane and 30 mM phosphate buffer (pH 8.0) 
prior to depletion. The total protein recovered in supernatants after precipitation with 14% 
(w/v) PEG was 53 ± 4% (n = 3) whereas RuBisCO was depleted by only 55 ± 7% (n = 3). For 
the desalted samples, eight proteins with sizes of 140, 115, 80, 70, 40, 35, 25 and 20 kDa 
(Figure III-2A, desalted precipitate, red arrows) were removed from the supernatant together 
with RuBisCO during PEG precipitation. Hence, desalting did not improve the enrichment of 
less abundant proteins but the PEG precipitation method [117] was modified to make it an 
effective and inexpensive alternative for the specific depletion of RuBisCO, allowing HCP 
antigen preparation. A concentration of 16% (w/v) PEG affected not only RuBisCO, but also 
precipitated other HCPs, which is why 14% (w/v) PEG was more suitable when preparing the 
N. tabacum extract for the immunization of rabbits. 
Table III.1: Extra HCPs detected in the RuBisCO-depleted homogenate (section II.6.2). These proteins 
were not detected in the non-depleted homogenate, probably due to the large amount of RuBisCO. 
Proteins marked in red were not detected in homogenate after RuBisCO depletion. 
Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00013344g0009.1 31 kDa RNA binding protein 34.5 2 
NbS00002522g0001.1 14 3 3 protein A 28.8 3 
NbS00011955g0007.1 Aldose 1 epimerase 31.7 2 
NbS00019305g0027.1 ATP synthase subunit beta, mitochondrial 59.7 3 
NbS00035335g0017.1 Calreticulin 2 calcium binding protein 47.3 2 
NbS00017751g0013.1 Cysteine synthase 34.2 2 
NbS00009495g0011.1 
Dihydrolipoyl dehydrogenase 1, 
mitochondrial 
56.8 2 
NbS00000250g0010.1 Enolase 56.6 2 
NbS00028064g0012.1 Fructose bisphosphate aldolase 42.8 9 
NbS00017344g0018.1 Glutamine synthetase 47.4 4 
NbS00018339g0012.1 Glycine cleavage system H protein 1 17.5 2 
NbS00034054g0003.1 Glycine rich RNA binding protein 15.6 3 
NbS00017754g0002.1 Glyoxylate_hydroxypyruvate reductase B 42.9 3 
NbS00016215g0013.1 Inorganic pyrophosphatase 50 3 
NbS00035212g0002.1 L ascorbate peroxidase 2 cytosolic 38.8 2 
NbC25737543g0001.1 Malate dehydrogenase 29.8 2 
giǀ32746733 
mRNA-binding protein precursor (Nicotiana 
tabacum) 
44.2 3 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00028679g0001.1 NAD dependent epimerase_dehydratase 34.3 2 
NbS00030132g0003.1 NADP binding Rossmann fold 33.6 4 
NDK1_TOBAC 
Nucleoside diphosphate kinase 1 (Nicotiana 
tabacum) 
16.3 6 
NbS00002520g0008.1 
Oxygen evolving enhancer protein 2, 
chloroplastic 
37.7 4 
NbS00005125g0015.1 Peroxisomal S 2 hydroxy acid oxidase 38.8 4 
NbS00022787g0008.1 Peroxiredoxin 30.2 4 
NbS00001361g0009.1 Phosphoglycolate phosphatase 40 5 
giǀ294440432 Plastidic aldolase (Nicotiana tabacum) 42.8 6 
NbS00011182g0007.1 Ribose 5 phosphate isomerase 29.8 2 
NbS00016026g0011.1 
Ribosome recycling factor, chloroplastic 
fragment 
32.6 2 
NbS00059057g0001.1 
Superoxide dismutase Fe, chloroplastic 
fragment 
28 3 
NbS00008412g0009.1 Transketolase 1 86.2 11 
NbS00007905g0010.1 Triosephosphate isomerase, chloroplastic 33.1 3 
Search database - [Nb….: Nicotiana benthamiana database (Sol Genomics), giǀ….: NCBInr 
database (green plants), NDK1_TOBAC: SwissProt database] 
Another RuBisCO depletion method based on sodium phytate/calcium chloride precipitation 
was also tested on the N. tabacum homogenate. A combination of 5 mM sodium phytate/ 
calcium chloride removed 48 ± 2% (n = 2) RuBisCO from the homogenate whereas 10 mM 
removed 73 ± 6% (n = 3) RuBisCO (Supplementary Figure VII-1). Similar results have been 
reported for soybean extracts but required a temperature of 42°C [116] which can lead to the 
degradation of thermolabile proteins [157, 158]. 
 Endotoxin removal/depletion from tobacco HCPs 
III.1.3.1  Endotoxin content of plants and bacteria 
Acceptable concentrations of endotoxins must be defined for injectable products, including 
those manufactured in plants [123, 159, 160]. Rabbits used for immunization have a mass of 
3‒5 kg [161] and samples for injection require endotoxin levels lower than 10 EU mg-1 HCP 
to meet the specifications described above [107, 162]. Although plants do not produce 
endogenous endotoxins [64] they can be colonized by Gram-negative bacteria that produce 
endotoxins [163]. Furthermore, in the case of transient expression strategies using 
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Agrobacterium tumefaciens [164], millions of bacteria are deliberately introduced into the 
spaces between leaf mesophyll cells, thereby substantially increasing the potential endotoxin 
load [165]. Accordingly it was found that endotoxin levels were ~200-fold higher in extracts 
from infiltrated N. benthamiana plants compared to wild type N. benthamiana and N. 
tabacum (Figure III-3). This increase correlated well with the endotoxin content of A. 
tumefaciens determined in several infiltration suspensions of OD600 = 1.0. 
 
Figure III-3: Endotoxin levels in leaves from N. tabacum and N. benthamiana (wild type and infiltrated 
with A. tumefaciens) were compared to the levels of endotoxin present in A. tumefaciens solutions used for 
infiltration. Error bars indicate the standard deviation (n ≥ 3). 
III.1.3.2  Endotoxin removal from wild-type N. tabacum and infiltrated N. benthamiana 
extracts 
The absence of endotoxins is one of the widely-reported safety advantages of plants over 
microbial systems [166]. Polymyxin B agarose [167] was tested to remove adventitious 
endotoxin from wild-type tobacco extract which can be present due to natural colonization of 
the plants by bacteria. The endotoxin level in the wild-type extract was ~37 EU mg-1 HCPs 
and this was reduced to 2.0 EU mg-1 HCPs after passage through Polymyxin B agarose 
(Figure III-4B). This is well below the target threshold of 10 EU mg-1 HCPs. Even a few ng 
mL-1 of endotoxin can cause fatal septic shock to animals [106, 107, 125, 168] depending on 
the dose and mode of administration. Several other methods have already been developed to 
remove endotoxins including ion-exchange chromatography, ultrafiltration [123, 169] and 
phase-separation [170, 171]. However, these methods are usually applied to highly-purified 
proteins (e.g. before final sterile filtration and formulation) and are thus optimized for binary 
separations. Hence, they were unlikely to be suitable when, as in the tobacco extracts 
described herein, a mixture of >100 proteins must be separated from endotoxins with a 
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guaranteed high recovery for each HCP at the same time. The variable size of endotoxins and 
their ability to bind proteins [172, 173] can make the separation even more difficult, 
especially because the binding can depend on pH and buffer composition [107, 125]. 
 
Figure III-4: Endotoxin removal from N. tabacum and N. benthamiana homogenates (section II.8). A. 
Various methods were tested for endotoxin removal and protein recovery. Error bars indicate standard deviation 
(n ≥ 3). B. A single Polymyxin B step was sufficient to reduce endotoxin levels below a threshold of 2 EU mg-1 
for N. tabacum extracts, whereas three passes through FiberFlo EN (first pass – brown color, second pass – red 
color and third pass – orange color) and a subsequent Polymyxin B step were required for N. benthamiana 
infiltrated with A. tumefaciens. 
In the case of N. benthamiana plants infiltrated with bacteria, the abilities of Polymyxin B 
agarose [167] and EndoTrap blue resin [174] to remove the higher endotoxin load were 
compared, and neither method was able to reduce the initial toxin content of 10,300 ± 2000 
EU mg-1 HCPs to < 10 EU mg-1 HCPs (Figure III-4A). Therefore, these methods were 
supplemented with UF using a 1000-kDa MWCO membrane in the presence of 0.3% (v/v) 
ricinus oil [175]. This resulted in the removal of 96% (n = 2) of the initial endotoxin load but 
was still insufficient to meet the specifications. An extra step was also required to remove the 
residual oil which can be toxic if injected into animals (0.03–0.06 µg kg-1 rabbit) [176]. 
The filtered plant extract was also passed three times through a FiberFlo EN filter, which has 
affinity for endotoxins [177, 178]. The endotoxin levels declined with each passage (Figure 
III-4B) and more than 98% was removed after the final passage, reducing the endotoxin load 
in the filtrate to 33 EU mg-1 HCP. By applying the methods described above, the endotoxin 
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content was reduced to 1.59 EU mg-1 (FiberFlo EN filter followed by Polymyxin B agarose) 
or 1.43 EU mg-1 (FiberFlo EN filter followed by EndoTrap blue resin). These values fell 
below the threshold of 10 EU mg-1 [107, 162] and the N. benthamiana extract was therefore 
used along with the N. tabacum extract (Section III.1.3.2) for the immunization of rabbits.  
Polymyxin B agarose removed 95 ± 4.7% (n = 3) of the total endotoxin content when applied 
to N. tabacum extracts with a relatively low endotoxin load (~35 EU mg-1 HCP) and achieved 
a protein recovery of 91 ± 1.5% with a consumables cost of 20% compared to EndoTrap blue. 
In contrast, N. benthamiana extracts following infiltration with A. tumefaciens had a greater 
endotoxin load and its removal was more challenging. Three passes through a FiberFlo EN 
filter removed 98 ± 0.6% of the endotoxin content from N. benthamiana extracts (n = 3) and 
the remaining endotoxin was reduced to safe levels by EndoTrap blue or Polymyxin B 
agarose. This latter method combining FiberFlo EN with Polymyxin B agarose was the 
simplest, fastest and most economical way to remove the high endotoxin burden from extracts 
of N. benthamiana plants infiltrated with A. tumefaciens. The additional FiberFlo EN filter 
increased the costs for endotoxin removal by a factor of 2 for infiltrated plants compared to 
wild-type plants, but this is only relevant for HCP preparation from crude extracts and does 
not apply to recombinant protein products that undergo purification by chromatography.  
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III.2  Development and characterization of polyclonal antibodies against 
tobacco HCPs 
Rabbits and goats are often used for antibody production because they require minimal 
handling and provide enough antisera for immunoassay development [161]. Antibodies were 
therefore raised against wild-type N. tabacum (SR1 and K326) HCPs, wild-type RuBisCO-
depleted N. tabacum (SR1 and K326) HCPs and N. benthamiana (agroinfiltrated) HCPs, 
prepared as described in Section III.1, by immunizing rabbits and goats. The bleeds were 
collected, frozen at –80°C (Table II.4) and analyzed together after the final bleed. The 
antibodies were characterized by 1-D and 2-D western blots and ELISA. 
 Anti-HCP antibodies: characterization by 1-D and 2-D western blot 
The presence of antibodies against N. tabacum HCPs (NtHCPs), RuBisCO-depleted N. 
tabacum HCPs (NtRdHCPs) and N. benthamiana HCPs (NbHCPs) in the corresponding 
antisera was confirmed by 1-D western blot and densitometric analysis (Figure III-5). 
Compared to a control gel stained with Coomassie Brilliant Blue, the coverage of HCP bands 
detected by antisera from the first bleeds was ~55% (N. tabacum) and ~80% (N. 
benthamiana) increasing to 100% for the pooled bleeds of the RuBisCO-depleted N. tabacum 
extract and the N. benthamiana extract (Figure III-5). 
 
Figure III-5: Rabbit antisera (bleeds) against N. tabacum extract (blue), RuBisCO-depleted N. tabacum 
extract (green) and N. benthamiana extract (red), taken at different time points after immunization, were 
used to detect tobacco HCPs on 1-D western blots (section II.14) and the number protein bands was 
compared to a Coomassie Brilliant Blue G-250 control (dashed lines). Abbreviations: dpi = days post 
immunization.  
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The western blot of pooled bleeds representing NtRdHCPs revealed two extra bands (~115 
and ~100 kDa) compared to the non-depleted extracts. The individual and pooled bleed 
obtained after immunization with N. tabacum, RuBisCO-depleted N. tabacum and N. 
benthamiana were also characterized by 1-D western blot (Supplementary Figure VII-2, 
Figure VII-3 and Figure VII-4). 
Similar results were obtained with antibodies purified from rabbit sera by Protein A 
chromatography (Figure III-6A). The ~115 kDa and ~100 kDa bands (green arrows) appeared 
more intense when antisera from rabbits immunized with NtRdHCPs were used rather than 
antisera against the non-depleted extract. Furthermore, an additional band at ~130 kDa 
appeared (red arrow) but a ~40 kDa band was weaker. Despite the depletion of RuBisCO, the 
corresponding antisera still detected ~15 and ~50 kDa bands representing this enzyme. 
Antisera against NbHCPs also recognized ~100% (n = 2, densitometric analysis) of the 
protein bands detected by Coomassie Brilliant Blue (Figure III-6). A ~40 kDa protein band 
that was detected with Coomassie was not detected by western blotting. Interestingly, two 25‒
30 kDa proteins in the NbHCPs sample appeared to be highly immunogenic because they 
were not detected with Coomassie but nevertheless generated an intense band in the 
subsequent immunoblot. 
Therefore, in the course of immunization, an immune response was raised against all three 
antigen preparations (NtHCPs, NtRdHCPs and NbHCPs) that covered >90% of the HCPs 
according to 1-D western blot analysis. 
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Figure III-6: Gel-based tobacco HCP analysis. A. One-dimensional western blot (section II.14) of N. tabacum 
and N. benthamiana homogenates probed with the corresponding antibodies. M – molecular mass marker; C – 
Coomassie-stained homogenate; Nt – rabbit--N. tabacum primary antibody; Nt-dp – rabbit--N. tabacum 
RuBisCO-depleted primary antibody; Nb – rabbit--N. benthamiana primary antibody. Red and green arrows 
indicate additional bands or those appearing more prominent when Nt-dp was used instead of Nt. B. Two-
dimensional SDS-PAGE (section II.10) of NtHCPs after silver staining. C. NtHCPs detected by 2-D western blot 
(section II.15) probed with antibodies against N. tabacum HCPs. D. NtHCPs blot probed with antibodies against 
NtRdHCPs. Green and red arrows highlight spots that appeared more prominent when antibodies were used 
against NtHCPs and NtRdHCPs, respectively. 
Antibodies against NtHCPs and NtRdHCPs detected 360 and 396 protein spots, respectively 
(Figure III-6 C and D), in 2-D blots with 7-cm IEF stripes. Antibodies against NbHCPs 
detected 1069 protein spots on 2-D blots with 17-cm IEF stripes (Figure III-7B) whereas only 
843 were detected by silver staining (Figure III-7A). Furthermore, 2-D western blots using 
NtHCPs revealed 36 additional protein spots (Figure III-6D, red arrows) when antibodies 
raised against RuBisCO-depleted HCPs were used rather than the non-depleted counterpart, 
probably reflecting the lower RuBisCO-specific immune response. In contrast, 18 spots were 
absent or less intense when antibodies against the non-depleted extract were used (Figure 
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III-6C, green arrows) but these spots were present when antibodies were used against the non-
depleted extract. In comparison to silver-stained 2-D gels, 5 ± 1% (n = 2) more protein spots 
were detected by 2-D western blots when antibodies against NtHCPs were used. Because both 
polyclonal antibody preparations against NtHCPs detected unique protein spots, a mixture 
both sera would be most suitable for DSP quality control because this enables the detection of 
the largest number of individual HCPs. The use of extracts depleted for the most abundant 
HCP (RuBisCO) was straightforward and avoided antigenic competition resulting in an 
antibody response even against scarce HCPs. The combined use of depleted and non-depleted 
extracts is suitable as an alternative to procedures such as cascade immunization [99] or 
passive pre-immunization [100], which require more sophisticated and more cumbersome 
techniques. 
 
Figure III-7: Evaluation of N. benthamiana anti-HCP antibody. A. Two-dimensional SDS-PAGE (section 
II.10) of NbHCPs after silver staining. B. NbHCPs detected by 2-D western blotting (section II.15) probed with 
anti-HCP antibodies. Red and green arrows indicate spots that were detected more effectively by silver staining 
and immunodetection, respectively. 
NbHCPs-specific antibodies detected ~22 ± 7% more spots than silver staining after 2-D 
western blotting, underlining the high sensitivity of the immunochemical method and its 
suitability for biopharmaceutical quality control. The extra spots were distributed over the 
entire size range (20–100 kDa) and pI rang (4.5–6.0) of the gel indicating an overall and 
broad increase in the detection of HCPs by anti-HCP antibodies with no bias towards 
particular physicochemical properties.  The antisera could be useful for generic HCP detection 
during early process development, when antisera specific for the production of a certain 
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protein are not yet available. They could also be used to distinguish between product-related 
and process-related impurities and determine the efficiency of different chromatography steps. 
 Anti-HCP antibodies: characterization by indirect ELISA 
The binding of antibodies to their corresponding HCP antigens was confirmed by ELISA. 
Titers of 1:128,000 for anti-HCP antibodies raised against NtHCPs and NtRdHCPs (Figure 
III-8A) and 1:256,000 for antibodies raised against NbHCPs (Figure III-8B) were observed. 
Antibody titers for individual bleeds post immunization are summarized in Supplementary 
Table VII.2 and Table VII.3 along with their titration curves (Supplementary Figure VII-5) 
for immunization with NtHCPs, NtRdHCPs and NbHCPs. 
 
Figure III-8: Indirect ELISA (section II.17.1) was used to determine antibody titers purified from rabbits 
immunized against N. tabacum (A) and N. benthamiana (B) HCPs. For the N. tabacum extract, titers of 
antibody from rabbits immunized with the RuBisCO-depleted extract were also determined. Error bars indicate 
standard deviation (n ≥ 3). 
Based on a signal-to-noise ratio threshold of ≥2 (OD405nm), high antibody titers [179] of 
1:128,000 and 1:256,000 were achieved against the mixtures of antigens from N. tabacum and 
N. benthamiana, respectively. The difference may reflect the inherent variability of biological 
systems, the need to use different animals for each immunization and the difference in the 
origin of the antigen preparations [180, 181]. Despite the titer differences, anti-HCP 
antibodies against both species were able to detect HCPs at concentrations as low as ~2 ng 
mL-1 (sections III.5.1.1 and III.7.4) and are therefore suitable for downstream process 
development. The method could facilitate the design of chromatography methods for the 
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purification of PMPs by allowing the rapid testing of HCP levels after each process step. It 
could also expand the panel of quality control assays that can routinely be used to determine 
the quality of APIs produced in plants. The generation of polyclonal antibodies following the 
depletion of abundant proteins such as RuBisCO allowed the more sensitive detection of less-
abundant proteins. The PEG depletion method is rapid and inexpensive, and can be adapted to 
other plant species to facilitate the development of a similar HCP detection assays. 
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III.3   Immunization 2 of tobacco HCPs in rabbits and goats 
The immunization and characterization procedure described above (sections II.12, II.14 and 
II.17) was repeated with rabbits and goats using wild-type N. tabacum (K326), RuBisCO-
depleted N. tabacum (K326) and agroinfiltrated N. benthamiana extracts as antigens. 
 Characterization of anti-HCP antibodies raised against N. tabacum, RuBisCO-
depleted N. tabacum (K326) and N. benthamiana HCPs 
III.3.1.1  Antibody purification from rabbits and goats (immunization 2)  
Antibodies were purified from rabbit antiserum by Protein A chromatography. The 
concentrations of NtHCPs antibodies raised in rabbits (NtAR) and NtRdHCPs antibodies 
raised in rabbits (NtRdAR) were 10 and 13 mg mL-1 respectively, as determined by  SPR 
spectroscopy. 
The anti-HCP antibodies raised against tobacco HCPs in goats were purified by a combination 
of Protein A (Figure III-9) and Protein G chromatography (to check purification efficiency) or 
Protein G alone because Protein A is weak binder of goat IgGs [182]. Accordingly, the 
recovery of antibodies was about threefold higher for Protein G (Table III.2, Figure III-10). 
 
Figure III-9: Purification of anti-HCP antibodies produced in goats (section II.13). Chromatogram 
representing the purification of antibodies raised against N. tabacum HCPs on Protein A (black) and Protein G 
(red, with protein A flow-through as the load). 
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Table III.2: Anti-HCP (N. tabacum and N. benthamiana) antibodies recovered from Protein A (section 
II.13) and Protein G (section II.13) purification of goat antiserum (1 mL antiserum contains ~20 mg total 
IgG). 
S. No.: Sample Antibodies recovered [mg] 
01 Protein A (NtAG and NtRdAG) 5 
02 Protein G [Protein A FT as load] 15 
03 Protein G (NtAG and NtRdAG) 19 
04 Protein G (NbAG) 17 
NtAG – N. tabacum antibody produced in goats 
NtRdAG – N. tabacum (RuBisCO-depleted) antibody produced in goats 
NbAG – N. benthamiana antibody produced in goats 
 
 
Figure III-10: Western blot (Section II.14) of antiserum before and after purification on Protein A (section 
II.13) or Protein G (section II.13). Lane 1: Pre-stained protein marker Lane 2: Protein A load Lane 3: Protein 
A flow-through Lane 4: Protein A eluate Lane 5: Protein G flow-through (Protein A flow-through was the load) 
Lane 6: Protein G eluate. Donkey anti-goat (H+L) antibody (1:5000 dilution) was used for detection. Purple 
arrows indicate the antibody heavy chain and black arrows indicate the light chain. 
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III.3.1.2   Anti-HCP antibodies: characterization by 1-D western blot and ELISA 
The anti-HCP antibodies produced in rabbits and goats against the tobacco HCPs (N. tabacum 
K326, RuBisCO-depleted N. tabacum K326, and N. benthamiana) were characterized by 
ELISA and western blot.  
 
Figure III-11: Immunoreactivity (Section II.14) of N. tabacum (K326) and N. benthamiana HCPs against 
their anti-HCP antibodies (unpurified and purified) produced in rabbits and goats. Lane 1: Pre-stained 
protein marker Lanes 2 and 7: NtHCPs (K326) and NbHCPs LDS-PAGE stained with Coomassie Brilliant 
Blue. Lanes 3–6 and 8–11: Western blots of HCPs against their corresponding anti-HCP antibodies Lane 3: N. 
tabacum antibody produced in rabbits (NtAR) and N. tabacum (RuBisCO-depleted) antibody produced in rabbits 
(NtRdAR) (unpurified). Lane 4: NtAR and NtRdAR (purified). Lane 5: NtAG and NtRdAG (unpurified). Lane 
6: NtAG and NtRdAG (purified). Lane 8: N. benthamiana antibody produced in rabbits (NbAR) (unpurified). 
Lane 9: NbAR (purified). Lane 10: NbAG (unpurified). Lane 11: NbAG (purified). Green box shows the 
purified version of anti-HCP antibodies generated in rabbits and goats. Goat anti-rabbit and donkey anti-goat 
secondary antibodies (1:5000 dilution) were used as appropriate. 
Anti-HCP antibodies from rabbits and goats against all HCP preparations detected several 
HCPs by western blot (Figure III-11). Densitometric analysis showed that anti-HCP 
antibodies (unpurified and purified) covered all the proteins detected by LDS-PAGE and 
Coomassie staining of the corresponding HCPs. A protein band at ~40 kDa was detected more 
sensitively by the goat anti-HCP antibodies compared to the rabbit anti-HCP antibodies. This 
may reflect differences in the immune response of different species to the same protein [161, 
181]. 
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The N. tabacum and N. benthamiana anti-HCP antibodies from rabbits and goats were also 
characterized by indirect ELISA. The titers of antibodies against N. tabacum (K326) in rabbits 
and goats were 1:128,000 and 1:16,000, respectively, whereas the titers of antibodies against 
N. benthamiana in rabbits and goats were 1:512,000 and 1:8000 respectively. Similar titers 
were also achieved against N. tabacum (SR1) in rabbits (section III.2.2). However significant 
differences in titer were observed when comparing the rabbit and goat antisera. Differences in 
titer both within and between animal species may reflect different immune responses against 
the same HCPs [98, 180]. This may result from the complexity of biological systems [181], 
and may also depend on the gender and age of the animals [161]. However the differences in 
titer did not affect the quality of antisera produced against HCPs because in all cases the 
antisera were able to detect most HCPs (Figure III-11). 
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III.4  Immunoassay development for tobacco HCPs 
Western blot and ELISA were used for the development of assays using purified anti-HCP 
antibodies raised against tobacco HCPs. The successful detection of HCPs from N. tabacum 
and N. benthamiana using their corresponding anti-HCP antibodies was already confirmed by 
1-D and 2-D western blot (section III.2.1). 
 Limit of detection (LOD) analysis by western blot (N. tabacum) 
As stated above, RuBisCO is the most abundant tobacco protein, representing 30–50% of 
TSP. Only RuBisCO was detected when the tobacco homogenate was diluted to a level of ng 
mL-1 because the other proteins were diluted below the detection threshold (data not shown). 
The other proteins were therefore exposed to the anti-HCP antibodies by depleting RuBisCO 
from the N. tabacum homogenate before LOD analysis. After removing RuBisCO, the protein 
samples were separated by LDS-PAGE with the lanes loaded with a maximum of 6500 ng and 
a minimum of 1.3 ng TSP. The proteins were then transferred to a nitrocellulose membrane 
and the western blot is shown in Figure III-12. 
 
 
Figure III-12: LOD test for NtHCP (SR1) against corresponding anti-HCPs antibodies by 1-D western 
blot (section II.14). A. NtAR against NtHCP B.  NtRdAR against NtHCP Lane 1: Pre-stained protein marker 
Lane 2: 6500 ng total protein Lane 3: 650 ng Lane 4: 325 ng Lane 5: 162 ng Lane 6: 65 ng Lane 7: 32 ng 
Lane 8: 13 ng Lane 9: 6.5 ng Lane 10: 1.3 ng. The first antibody (anti-N. tabacum produced in rabbits) was 
diluted 1:1000 (3 µg mL-1) and the second antibody (goat anti-rabbit, H+L) was diluted 1:5000. 
A B 
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Downstream processing may remove RuBisCO completely but other less abundant proteins 
may remain and these need to be detected. Accordingly, the antibodies were able to detect 
proteins of ~140, ~100 and ~70 kDa when only 1.3 ng TSP was loaded (Figure III-12 lane 10) 
confirming their sensitivity towards NtHCPs and suggesting they would be likely to detect 
HCPs in the nanogram range during the manufacture of biopharmaceuticals.  
 LOD analysis by western blot (N. benthamiana) 
LOD analysis of antibodies against NbHCPs produced in rabbits was carried out using the 
same procedure described above. Different amounts of TSP (from 6500 ng to 1.3 ng) were 
separated by 1-D LDS-PAGE and transferred to a nitrocellulose membrane and the western 
blot is shown in Figure III-13. 
 
Figure III-13: LOD test for NbHCP against corresponding anti-HCPs antibodies by 1-D western blot 
(section II.14). Lane 1: Pre-stained protein marker Lane 2: 6500 ng total protein Lane 3: 650 ng Lane 4: 325 
ng Lane 5: 162 ng Lane 6: 65 ng Lane 7: 32 ng Lane 8: 13 ng Lane 9: 6.5 ng Lane 10: 1.3 ng. The first 
antibody (anti-N. benthamiana produced in rabbits) was diluted 1:1000 (3 µg mL-1) and the second antibody 
(goat anti-rabbit, H+L) was diluted 1:5000. 
Even in the presence of RuBisCO, antibodies developed against N. benthamiana HCPs were 
able to detect as little as 6.5 ng TSP (Figure III-13, arrow in lane 9, a protein of ~115 kDa 
along with RuBisCO). In lane 10 (1.3 ng TSP), the antibodies were still able to detect 
RuBisCO (shown by arrow). The LOD for N. benthamiana antibodies was therefore as low as 
1.3 ng, although the detection of less abundant proteins could be improved by RuBisCO 
depletion as shown in section III.4.1, indicating the sensitivity of the N. benthamiana anti-
HCP antibodies against their corresponding HCPs. 
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 LOD analysis by indirect ELISA (N. tabacum SR1 and N. benthamiana) 
The LOD is the minimum amount of antigen detected by anti-HCP antibodies (in this case by 
indirect ELISA) and was determined using checkerboard titration. The anti-HCP antibodies 
were detected using an enzyme-conjugated secondary antibody recognizing the primary 
antibody. The antigens (NtHCPs and NbHCPs) were coated onto a high binding plate with a 
starting concentration of 100 ng mL-1 and serially diluted over 11 wells. The anti-HCP 
antibodies raised against NtHCPs and NbHCPs in rabbits were added at a concentration of 
100 µg mL-1 in wells 1–12 and serially diluted through to G. Row H was used as a blank 
control lacking the primary antibody to identify false positive results produced by the 
secondary antibody binding to HCPs. Row 12 was used as a zero control (no antigen) to 
identify false positive signals produced by the secondary antibody binding to the blocking 
reagent. A result was considered positive if the value was ≥2 times the blank. The titration 
curve from the LOD experiments is shown in Figure III-14. 
 
Figure III-14: Indirect ELISA (section II.17) LOD test for tobacco HCPs against corresponding anti-
HCPs antibodies. A. LOD of N. tabacum anti-HCP antibodies B. LOD of N. benthamiana anti-HCP antibodies. 
The secondary antibody (goat anti-rabbit) conjugated with phosphatase was diluted 1:5000. The OD was 
measured at 405 nm. 
The LOD achieved for N. tabacum and N. benthamiana anti-HCP antibodies raised in rabbits 
was 3 ng mL-1 and 6 ng mL-1 at antibody concentrations of 6 µg mL-1 and 3 µg mL-1 
respectively (Figure III-14A and Figure III-14B). The N. tabacum and N. benthamiana anti-
HCP antibodies were similar in sensitivity with a LOD of 3 ng mL-1 HCPs. The sensitivity of 
the indirect ELISA depends on the secondary antibody binding to the primary, and can often 
be increased by using labeled antibodies for direct detection as discussed below. 
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 Antibody labeling with HRP 
The purified antibodies against NtHCPs and NbHCPs generated in rabbits were labeled with 
HRP (section II.18). The free enzyme remaining in the mixture is usually washed away and 
does not interfere with the assay, but removing the enzyme reduces the non-specific signal 
and increases the accuracy of the assay so it was removed by SEC. The resulting 
chromatogram for anti-N. tabacum antibody coupling is shown as an example in Figure 
III-15. 
 
Figure III-15: Coupling of anti-HCP antibodies (section II.18) to HRP and the removal of unbound 
enzyme by SEC. Chromatogram shows the separation of free enzymes from the antibody-enzyme coupled 
mixture. The coupled antibody-enzyme run chromatogram is shown in red and the only antibody run 
chromatogram is shown in black. Collected fractions are represented by the green area. Absorbance was 
measured at 280 nm.  
Before the conjugated antibodies were used in the ELISA, the coupling reaction was 
evaluated by SEC using a Sephacryl S-200 column. The collected fractions and the pure 
antibody were analyzed by SEC to determine their sizes (Figure III-15) and the 
characterization of individual samples is summarized Table III.3.  
Table III.3: Molecular size of antibody before and after labeling (from Figure III-15). 
Serial No.: Sample Molecular weight (kDa) 
01 Antibody 134 
02 Fractions 1–2 598 
03 Fraction 3 238 
04 Fractions 4–9 143 
05 Fractions 10–14 45 
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Fractions 1–2 (~598 kDa) confirmed that conjugation was successful. The free enzyme (~40 
kDa) was present in fractions 10–14 whereas the unlabeled anti-HCP antibodies (~240 kDa) 
were present in fraction 3. The difference in size between the anti-HCP antibodies before and 
after coupling depends on the number of coupled enzyme molecules, so the antibodies with 
fewer conjugates (fractions 4–9) may overlap with the uncoupled antibodies. These data were 
confirmed by direct ELISA. The difference in the size and the ELISA signal depends on the 
number of enzyme molecules coupled to the antibody which may differ from antibody to 
antibody due to number of available binding positions. The N. tabacum naïve and RuBisCO-
depleted anti-HCP antibodies were conjugated to HRP both as separate samples and as a 
mixture (section III.5.1.1) and the N. benthamiana anti-HCP antibodies were modified in the 
same manner. Directly labeling reduces the time and cost of assay development.  
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III.5  ELISA development 
ELISA is the method of choice in the pharmaceutical industry for the in vitro detection and 
quantification of analytes for quality assessment [83] and this assay also plays an important 
role during the regulatory clearance of pharmaceutical candidates [183]. Several variants are 
used, including direct, sandwich and competitive ELISAs, each with unique advantages and 
disadvantages. Direct ELISA is rapid and cost-effective, but because the antigen is directly 
coated onto a solid surface at high pH its characteristics may change and prevent detection. In 
contrast, a capture antibody is coated onto the solid surface in a sandwich ELISA so that the 
antigen is captured in its native state. This increases sensitivity but a second antibody 
recognizing a different epitope is required for detection and this involves an extra assay step. 
In a competition ELISA, a capture antibody is coated onto the solid surface and then the 
labeled antigen competes with an unlabeled antigen or alternative ligand to investigate 
binding specificity. 
 Direct ELISA development 
In a direct ELISA, the antigen is coated onto a substrate and is directly recognized by a 
detection antibody that may carry an intrinsic label or may be unlabeled and detected with a 
secondary antibody that binds specifically to the Fc region of the primary detection antibody. 
  Direct ELISA (http://history.cpet.ufl.edu/lm/elisa/content)  
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III.5.1.1  N. tabacum and N. benthamiana standard curves for HCP quantification 
The development of a direct ELISA was initially attempted using labeled antibodies against 
NtHCPs and NtRdHCPs (section III.4.4). Serial dilutions were used to establish an HCP 
standard curve, as shown in Figure III-16. 
 
Figure III-16: Direct ELISA (section II.17.1) standard curve for the quantification of N. tabacum (SR1) 
HCPs using anti-HCP antibodies. A. N. tabacum direct ELISA standard curve generated using NtAR B. N. 
tabacum direct ELISA standard curve generated using NtRdAR. The anti-HCP antibodies were labeled with 
HRP and diluted 1:500. Optical density was measured at 405 nm. Linearity of the standard curve is represented 
by R2. Error bars show the standard deviations (n ≥ 3). The graph was plotted after subtracting the blank value. 
The direct ELISA was calibrated over the range of 3–100 ng mL-1 using labeled NtAR and 
NtRdAR standards prepared by serial dilution, resulting in a linear fit over the tested antigen 
concentrations. The R2 value achieved using both anti-HCP antibodies was ≥0.99 and the 
relative standard deviation (RSD) was ~4% for the N. tabacum anti-HCP antibodies and ~2% 
for the RuBisCO-depleted N. tabacum anti-HCP antibodies. Six standards were used 
excluding the blank, which is the minimum requires for a bio-analytical assay [184]. A linear 
assay with an R2 value close to the predicted value of 1.0 is considered a good fit and makes it 
easier to calculate unknown sample concentrations [94, 185, 186]. 
In the next step, the labeled N. tabacum and RuBisCO-depleted N. tabacum anti-HCP 
antibodies were pooled in a 1:1 ratio (v/v) to determine their combined effect on assay 
linearity. As shown in section III.2.1, both sets of anti-HCP antibodies detected unique HCPs 
so pooling them covers a wider range. The pooled HCP standard covered the concentration 
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range 2.5–90 ng mL-1. During this phase of assay development, the standards were used more 
precisely with an equal interval between them and the stability of assay linearity was tested 
throughout the time interval without stopping the reaction. The standard curves produced 
from the combined detection anti-HCP antibodies are shown in Figure III-17. 
 
Figure III-17: Direct ELISA (section II.17.1) standard curve for the quantification of N. tabacum (SR1) 
HCPs using pooled anti-HCP antibodies. A. Read @ 30 min B. Read @ 60 min. The N. tabacum and 
RuBisCO-depleted N. tabacum anti-HCP HRP-labeled antibodies were pooled in a 1:1 ratio and diluted 1:500. 
Error bars show the standard deviation (n ≥ 3). Optical density was measured at 405 nm. R2 values confirmed the 
linearity of the assay. The graph was plotted after subtracting the blank value. 
The combination of anti-HCP antibodies used for the standard calibration curve also produced 
a linear fit, with an R2 value of ≥0.99 and an RSD of ~2%. The readout for the assay was also 
measured at two intervals (30 min and 60 min) which showed no change in regression or 
linearity. This confirmed that assay performed well over a range of standards with a 
sensitivity of ~3 ng mL-1 and also indicated the robustness of the assay. A non-serial dilution 
procedure was used to prepare the standards in this phase of assay development (Figure 
III-17). The linearity and regression showed that different dilution schemes do not affect the 
linearity of the assay which emphasizes its stability and robustness.  
A direct ELISA for N. benthamiana HCPs was established as described above. The standard 
antigen concentration was tested over the range 2.5–90 ng mL-1 using the dilution strategy 
described for N. tabacum (Figure III-17). The standard curved obtained for N. benthamiana 
using anti-HCP antibodies is shown in Figure III-18. 
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Figure III-18: Direct ELISA (section II.17.1) standard curve for the quantification of N. benthamiana 
HCPs using anti-HCP antibodies. A. Read @ 40 min. B. Read @ 60 min. Direct detection N. benthamiana 
anti-HCP HRP-labeled antibodies diluted 1:500. Error bars show the standard deviations (n ≥ 3). The graph was 
plotted after subtracting the blank value. The initial OD measurement was 10 min longer for N. benthamiana 
compared to N. tabacum because of slow signal development. 
The linearity and sensitivity of the direct ELISA for N. benthamiana was similar to N. 
tabacum (2.5–90 ng mL-1 and ~3 ng mL-1). The regression for the N. benthamiana standards 
was ≥0.99 which is considered a good fit curve [185] and the RSD was ~3.7%. The assay was 
observed from 40 to 60 min without stopping the reaction and linearity was maintained. There 
was little difference between the 2.5 and 5 ng mL-1 standards after 60 min perhaps reflecting 
the attenuation of the saturation point in the lower range after 60 min while the higher 
standards still remained linear.   
Both direct ELISAs (N. tabacum and N. benthamiana) produced similar linear standard 
curves during assay development. The direct ELISA for both species complies with the linear 
fit curve over a range of 2.5–90 ng mL-1 with an R2 value ≥0.99 and a RSD of < 5%. The 
direct ELISA offers a wide range of standard working protocols with high sensitivity. Even 
though linearity was observed up to 100 ng HCP mL-1 it will be interesting to see how the 
assay performs at even higher HCP concentrations. The direct ELISAs will be used in future 
studies for the quantification of HCPs during the downstream processing of PMPs.   
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  Sandwich ELISA model for N. tabacum (SR1) 
The anti-HCP antibodies against N. tabacum (SR1) HCPs raised in rabbits were next used to 
develop a sandwich ELISA procedure for HCP quantification. The same rabbit anti-HCP 
antibodies were used for capture and detection because they are polyclonal and therefore 
likely to recognize multiple epitopes on each HCP, but unlabeled antibodies were used for 
coating (10 µg mL-1) whereas HRP-labeled antibodies were used for detection diluted 1:500. 
The standard curve from the sandwich ELISA is shown in Figure III-19.  
 
Figure III-19: Sandwich ELISA (section II.17.2) standard curve for N. tabacum HCPs (SR1) using pooled 
anti-HCP antibodies (N. tabacum and RuBisCO-depleted N. tabacum anti-HCP antibodies). Optical density 
was measured at 405 nm. Error bars show the standard deviations (n ≥ 3). 
The sandwich ELISA yielded a linear fit curve over the range 5–90 ng mL-1 with an R2 value 
of ≥0.98 and an RSD < 5%. Although a linear fit was achieved using the same anti-HCP 
antibodies for capture and detection, the optical difference between the lowest and highest 
standards was only ~0.4, perhaps reflecting nonspecific cross-reactivity between the coating 
or detection antibodies due to their high concentrations (sandwich ELISA is more sensitive 
than direct ELISA). To eliminate this cross-reactivity, the same assay was carried out using a 
low concentration of coating antibody (1 µg mL-1) and the same concentration of detection 
antibody as before (1:500). A similar linear fit curve was observed (data not shown) but again 
there was little optical difference between the standards. Furthermore, the blank control with 
no coating antibody gave a low background in both cases whereas the zero control with no 
antigen yielded a high background. This confirmed that cross-reactivity between the capture 
and detection antibodies probably explained the low resolution between the standards and the 
 III. Results and discussion                                                                                              Page 52 
 
Institute for Molecular Biotechnology at the RWTH Aachen University 
PhD thesis 2015 by Zulfaquar Ahmad Arfi 
 
high background in the zero control. Further optimization was therefore carried out to reduce 
cross-reactivity (section III.5.4). 
 Sandwich ELISA model for N. tabacum (K326) 
The HCPs from N. tabacum (K326) were used to produce anti-HCP antibodies in goats as 
well as rabbits. Therefore, in this case it was possible to use anti-HCP antibodies produced in 
goats for coating and HRP-conjugated anti-HCP antibodies produced in rabbits for detection. 
The standard curve obtained for this sandwich ELISA is shown in Figure III-20. 
 
Figure III-20: Sandwich ELISA (Section II.17.2) standard curve for N. tabacum HCPs (K326) using 
pooled anti-HCP antibodies (N. tabacum and RuBisCO-depleted N. tabacum anti-HCP antibodies). The 
coating antibody (goat anti-HCP) concentration was 5 µg mL-1 whereas the detection antibody (rabbit anti-HCP) 
was diluted 1:500. The optical density was measured at 405 nm. Error bars show the standard deviations (n ≥ 3). 
Significant cross-reactivity was observed between the anti-HCP antibodies produced in goat 
and rabbit even though a linear fit curve was achieved with an R2 value ≥0.98 and an RSD of 
1%. The cross-reactivity was confirmed by the high background signal in the zero control and 
the poor resolution among the standards, as described in more detail above. 
Several approaches have been developed to reduce or eliminate cross-reactivity between 
antibodies, including the optimization of concentrations as described in the previous section. 
Another approach involves panning one antibody against the other bound to a solid matrix to 
remove cross-reacting antibodies. Such antibodies are usually purified on a matrix containing 
Protein A (for antibodies produced in rabbits) or protein G (for antibodies produced in goats). 
However, other immunoglobulins are co-purified and could interfere with the assay 
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parameters. This type of interference can be usually eliminated by purifying the anti-HCP 
antibodies on an affinity columns loaded with HCPs, and this may also help to reduce cross-
reactivity. 
As discussed above, the first attempt to reduce cross-reactivity between the HCP-specific 
capture and detection antibodies (both from rabbits) involved the optimization of antibody 
concentrations (section III.5.4) to 2 µg mL-1 and 1 µg mL-1 respectively. A similar strategy 
was applied in the sandwich ELISA in which the capture antibodies were produced in goats 
and the detection antibodies in rabbits. The second attempt to reduce cross-reactivity involved 
passing the antibodies through an HCP-specific affinity column. The third strategy involves 
panning each population of antibodies against each other to remove binders, an approach that 
has already been used to remove anti-HCP antibodies that cross-react with a monoclonal 
antibody product manufactured in plants (Sections II.19 and III.6.3.1). 
 Reducing the cross-reactivity of rabbit anti-HCP antibodies 
As discussed in section III.5.2, the anti-HCP antibodies produced in rabbits produced a higher 
background when the coating antibody was used at a concentration of 10 µg mL-1 and the 
detection antibody used diluted 1:500. A checker board titration (section II.17.3) between the 
rabbit anti-HCP capture antibody (4 µg mL-1) and the HRP-labeled rabbit anti-HCP detection 
antibody (diluted 1:500, to ~2 µg mL-1) gave the results shown in Figure III-21. 
 
Figure III-21: Checker board titration (section II.17.3) of rabbit anti-HCP capture antibody and HRP-
labeled rabbit anti-HCP detection antibody. The assay was carried out to determine the concentrations 
required to avoid cross-reaction. Optical density was measured at 405 nm.   
The checker board titration (summarized in Table III.4) showed that the cross-reactivity 
between the capture and detection antibodies was highest at 4 µg mL-1 but the reactivity 
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decreased at lower concentrations. There was still slight cross-reactivity when the capture 
antibody and the detection antibody concentrations were 4 and 1 µg mL-1 respectively. No 
cross-reactivity was found between the capture and detection antibodies at the concentrations 
shown in Table III.4.   
Table III.4: checker board titration results for cross-reactivity between capture and detection antibodies. 
Serial No. Capture Ab [µg mL-1] Detection Ab [µg mL-1] Cross-reactivity 
1 2 1 No 
2 1 1 No 
3 2 0.5 No 
 
 Reducing cross-reactivity between goat and rabbit anti-HCP antibodies 
A checker board titration was also carried out for the anti-HCP antibodies produced against N. 
tabacum in goats and rabbits. The cross-reactivity was not reduced at different concentrations 
(data not shown) and similar cross-reactivity was observed between the goat and rabbit 
antibodies raised against N. benthamiana HCPs (data not shown). Additional strategies were 
therefore investigated such as coupling each population of anti-HCP antibodies to a matrix 
and panning with the other, or purifying both populations by passing them through an HCP 
affinity column. Thus far, the anti-HCP antibodies and HCPs have been coupled successfully 
to an NHS-activated matrix (section II.19) although the coupling appears unstable and bound 
antibodies or HCPs can leach under low-pH elution conditions (pH 3.0). The next challenge is 
therefore to optimize the elution conditions for this type of column to avoid leaching. Once 
the cross-reactivity is reduced, it will be possible to optimize the capture and detection 
antibodies for the establishment of a more robust sandwich ELISA model.    
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III.6  Applications of anti-HCP antibodies 
 Evaluation and identification of tobacco HCPs (product-related impurities) 
during purification (Protein A) 
HCPs from different tobacco species and varieties were analyzed to identify components that 
bind to Protein A resin, which is frequently used as an initial capture step [87, 187-191] 
during the production of monoclonal antibodies [192]. We used 1D and 2D gel 
electrophoresis combined with non-specific staining methods and HCP-specific 
immunodetection to track tobacco proteins binding to the Protein A resin in the presence and 
absence of two monoclonal antibodies (P2G12 or M12). In other systems, HCPs can co-purify 
with the product either by associating directly or indirectly with the product itself [91] or the 
chromatography ligands used for purification [193]. MS was used to identify HCPs eluting 
from Protein A columns under the same conditions as the antibodies and suggestions for 
separation are provided based on their physicochemical properties. 
TSP was extracted from tobacco plants (section II.4) and the filtered extract was injected into 
a Protein A column. Non-binding proteins were collected in the flow-through whereas the 
proteins bound to Protein A were eluted using low-pH buffer (pH 3.0). The eluate was 
concentrated (the eluate from wild-type plants was vacuum dried before analysis due to the 
low protein concentration) and analyzed by LDS-PAGE (Figure III-22) followed by MS for 
protein identification. The tobacco anti-HCP antibodies discussed earlier were used for 
western blot analysis to allow the further characterization of these HCPs.  
 
Figure III-22: LDS-PAGE analysis (section II.9) of eluate from a Protein A column (section II.13). Lane 1: 
Pre-stained protein marker Lane 2: Tobacco homogenate (Protein A load, 6.5 µg) Lane 3: Protein A eluate A.  
Wild-type N. tabacum SR1, 5.5 µg B. Wild-type N. tabacum K326, 6.2 µg C. Wild-type N. benthamiana, 3.1 µg 
D. Transgenic N. tabacum P2G12, 12.4 µg E. Transgenic N. tabacum M12, 15 µg (amounts in µg indicate the 
amount of protein loaded in each lane). 
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Each eluate from the Protein A column run was separated by electrophoresis followed by 
staining with SimplyBlue SafeStain, revealing several proteins that bind strongly to Protein A 
and eluted only under low-pH conditions (pH 3.0). Surprisingly a thick band was found in the 
K326 eluate at ~10 kDa (Figure III-22, orange arrow, lane B3) which was not seen in the 
other lanes. This was identified as a Protein A fragment, which confirmed that Protein A 
leaches under low-pH (3.0) conditions when exposed to K326 extracts. The ~50 and ~15 kDa 
bands in the Protein A load correspond to the presence of RuBisCO in the homogenate, 
whereas the ~55 and ~25 kDa bands in the lanes representing transgenic plants correspond to 
the antibody heavy and light chains. The abundance of the antibodies made it difficult to 
identify HCPs in the samples from transgenic plants. MS is often used to identify impurities 
such as HCPs during downstream processing [82, 190] and even to determine their 
chromatographic properties [194]. In order to identify the HCPs binding to Protein A, 
individual bands form the LDS-PAGE gel were analyzed by MS as shown in Table III.5. 
Table III.5: Proteins (product-related impurities) identified during Protein A purification.  
Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
Wild type N. tabacum SR1 
NbS00007132g0020.1 
2,3-bisphosphoglycerate independent 
phosphoglycerate mutase 
60.7 2 
NbS00017361g0009.1 
5-methyltetrahydropteroyltriglutamate 
homocysteine methyltransferase 
84.5 5 
NbS00000223g0005.1 40S ribosomal protein S13 17.8 2 
giǀ2467253 Annexin (Nicotiana tabacum) 35.8 3 
NbS00006011g0007.1 Beta D-glucosidase 65.7 7 
giǀ115473 
Carbonic anhydrase, chloroplastic 
(Nicotiana tabacum) 
34.5 4 
giǀ223593 
Carboxylase/oxygenase,RBP (Nicotiana 
tabacum) 
14.5 6 
giǀ58700509 
Chloroplast oxygen-evolving protein 16 kDa 
subunit  (Nicotiana tabacum) 
24.2 2 
NbS00025668g0009.1 
Chloroplast stem loop binding protein of 41 
kDa, chloropplastic 
48.6 2 
NbS00044621g0001.1 
Cyclophilin peptidyl prolyl cis-trans 
isomerase 
18.1 3 
NbS00020069g0017.1 
Ferredoxin dependent glutamate synthase 1, 
chloroplastic 
125.3 2 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00028064g0012.1 Fructose bisphosphate aldolase 42.8 11 
giǀ222051768 Germin like protein (Nicotiana tabacum) 21.4 3 
NbS00017344g0018.1 Glutamine synthetase 47.5 3 
NbS00022684g0008.1 
Glycine dehydrogenase decarboxylating, 
mitochondrial 
128 5 
NbS00004898g0002.1 Histone H4 11.4 3 
NbS00052402g0003.1 Heat shock 70 kDa protein, mitochondrial 73.2 2 
giǀ38325815 
Heat shock protein 70-3 (Nicotiana 
tabacum) 
70.9 11 
NbS00000666g0001.1 Histone H2B 15.7 6 
NbS00028294g0007.1 L-ascorbate oxidase 59.9 2 
giǀ10798652 Malate dehydrogenase (Nicotiana tabacum) 35.4 2 
NbS00022324g0009.1 Malate dehydrogenase 43.5 2 
giǀ15088626 Nictaba (Nicotiana tabacum) 19 2 
NbS00000211g0112.1 no protein name 43.1 2 
NbS00017066g0003.1 Oxalate oxidase germin 171 21.5 2 
NbS00015243g0004.1 
Oxido-reductase zinc binding 
dehydrogenase 
42.5 3 
NbS00010498g0007.1 Oxygen evolving enhancer protein 3 24.2 2 
giǀ8671350 Pectin methylesterase  (Nicotiana tabacum) 63.4 3 
NbS00011496g0007.1 Pectin methylesterase 3 122.3 5 
NbS00029780g0017.1 
Peptidyl prolyl cis trans isomerase CYP20 2 
chloroplastic 
22.3 2 
NbS00026425g0011.1 Peroxiredoxin 29.5 3 
NbS00005125g0015.1 Peroxisomal S 2 hydroxy acid oxidase 40.5 5 
NbS00018854g0005.1 Phosphoenolpyruvate carboxylase 1 109.5 5 
NbS00020603g0012.1 Phosphoglucomutase cytoplasmic 64.4 4 
NbS00001859g0006.1 Phosphoglycerate kinase 58.6 15 
giǀ2499497 
Phosphoglycerate kinase, chloroplastic 
(Nicotiana tabacum) 
50 9 
NbS00007805g0017.1 Phosphoribulokinase_uridine kinase 45.1 3 
NbS00002882g0020.1 
Photosystem II oxygen evolving complex 
protein PsbP 
23.8 2 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00049766g0015.1 
Photosystem II stability_assembly factor 
HCF136 
71.3 2 
giǀ294440432 Plastidic aldolase (Nicotiana tabacum) 42.8 11 
giǀ194396261 Plastid transketolase  (Nicotiana tabacum) 80 4 
NbS00011015g0025.1 
Presequence protease 1 
chloroplastic_mitochondrial 
127.3 3 
giǀ1255951 PS60  (Nicotiana tabacum) 60 2 
giǀ11465965 RuBisCO large subunit (Nicotiana tabacum) 52.8 16 
NbS00033391g0006.1 
RuBisCO large subunit-binding protein 
subunit alpha 
59.6 3 
giǀ30013663 
RuBisCO small subunit (Nicotiana 
tabacum) 
20.4 8 
NbS00019758g0008.1 Serine glyoxylate aminotransferase 43.9 4 
NbS00043086g0003.1 sedoheptulose bisphosphatase 33.5 5 
giǀ100284 
Superoxide dismutase [Fe] (Nicotiana 
tabacum) 
25.4 3 
giǀ21912927 
Thioredoxin peroxidase (Nicotiana 
tabacum) 
29.8 3 
NbS00002344g0006.1 Translationally controlled tumor protein 19.6 2 
 Wild type N. benthamiana   
NbS00003907g0013.1 40S ribosomal protein SA 32.9 3 
NbS00004792g0016.1 
ATP dependent Clp protease ATP binding 
subunit clpA 
104.3 4 
NbS00042416g0009.1 
ATP dependent Clp protease ATP binding 
subunit ClpC 
24.2 2 
NbS00019305g0027.1 ATP synthase subunit beta 59.8 4 
NbS00015227g0002.1 ATP synthase subunit beta chloroplastic 18.9 2 
NbS00016159g0006.1 Carbonic anhydrase chloroplastic 32.7 3 
NbS00026247g0013.1 D glycerate 3 kinase chloroplastic 51.7 4 
NbS00013225g0002.1 Elongation factor Ts 115.4 2 
NbS00005953g0021.1 Fructose 1,6-bisphosphatase class 1 45.4 2 
NbS00004219g0021.1 Fructose bisphosphate aldolase 50.1 4 
NbS00022684g0008.1 
Glycine dehydrogenase decarboxylating 
mitochondrial 
129.1 2 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00017344g0018.1 Glutamine synthetase 47.8 4 
NbS00014585g0006.1 Glutathione peroxidase 26 2 
NbS00016086g0007.1 Heme binding protein 2 26.4 3 
NbS00024531g0008.1 Leucine aminopeptidase 2 chloroplastic 60.5 2 
NbS00022324g0009.1 Malate dehydrogenase 44.1 2 
NbS00011957g0108.1 no protein name 41.6 4 
NbS00001169g0153.1 no protein name 36.5 4 
NbS00010454g0009.1 
Oxygen evolving enhancer protein 1 of 
photosystem II 
35,7 10 
NbS00028820g0007.1 
Oxygen evolving enhancer protein 2 
chloroplastic 
27.6 6 
NbS00026425g0011.1 Peroxiredoxin 29.7 5 
NbS00005125g0015.1 Peroxisomal S 2 hydroxy acid oxidase 38.9 5 
NbS00001859g0006.1 Phosphoglycerate kinase 58.8 3 
NbS00001361g0009.1 Phosphoglycolate phosphatase 40 4 
NbS00007805g0017.1 Phosphoribulokinase_uridine kinase 45.5 6 
NbS00004220g0013.1 
Photosystem II oxygen evolving complex 
protein PsbP 
26.4 3 
NbS00044787g0007.1 
Photosystem II stability_assembly factor 
HCF136 
64.8 10 
RBL_NICSY 
Ribulose bisphosphate carboxylase large 
chain (Nicotiana sylvestris) 
52.9 8 
NbS00047700g0013.1 
Ribulose bisphosphate 
carboxylase_oxygenase activase 2 
81.3 6 
NbS00042812g0008.1 
Ribulose bisphosphate carboxylase small 
chain 8B 
20.5 3 
NbS00033391g0006.1 
RuBisCO large subunit binding protein 
subunit alpha 
59.8 3 
NbS00016125g0003.1 
SEC14 cytosolic factor_phosphoglyceride 
transfer 
73.4 4 
NbS00008412g0009.1 Transketolase 1 86.7 17 
NbS00001671g0002.1 Triosephosphate isomerase cytosolic 17.1 3 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00010743g0018.1 
Unknown protein DS12 from 2D PAGE of  
leaf chloroplastic 
31.2 4 
Wild type N. tabacum K326 
NbS00006011g0007.1 Beta D glucosidase 66.2 5 
222051768 Germin like protein (Nicotiana tabacum) 21.4 2 
NbS00017066g0003.1 Oxalate oxidase germin 171 21.6 2 
NbS00029780g0017.1 Peptidyl prolyl cis trans isomerase CYP20 2 26.7 2 
giǀ4262869 
Ribulose-1,5-biphosphate carboxylase/ 
oxygenase large subunit (Nicotiana 
tabacum) 
52.9 12 
Transgenic N. tabacum (M12) 
giǀ119029720 Lectin (Nicotiana tabacum) 19 2 
NbS00009606g0002.1 
Pentatricopeptide repeat containing protein 
mitochondrial 
56.1 2 
giǀ73698122 Sam3 (Nicotiana tabacum) 19 2 
No proteins were detected in the transgenic N. tabacum (P2G12) preparation. Search database 
[Nb….: Nicotiana benthamiana database (Sol Genomics), giǀ….: NCBInr database (green 
plants), RBL_NICSY: SwissProt database] 
These results revealed the association between different tobacco proteins and the Protein A 
resin or non-specific ligands. Protein A was found in the N. tabacum (K326) and N. 
benthamiana eluates, but not in the N. tabacum (SR1) eluate. This may reflect the presence of 
different protease activities in different tobacco species. The cleavage of Protein A in the 
K326 process is also informative because it suggests this variety could express proteases 
against Protein A to a greater extent than other varieties thus affecting the purity of the 
product and requiring residual testing or even specific additional processing steps. The 
cleavage of Protein A also reduces the life span and efficiency of the resin, which 
automatically increases the cost of downstream processing. Therefore, the downstream 
processing parameters could be optimized with this variety to reduce the quantity of 
impurities eluted with the product, e.g. additional washing steps and modified elution 
conditions such as the high salt buffer used to remove certain HCPs before eluting the product 
from the Protein A column in the case of P2G12.  
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Many proteins were found in the eluate from wild-type plants after Protein A purification but 
only few in the transgenic plant lines expressing P2G12 and M12, perhaps reflecting the 
abundant signals from the antibody products masking other MS peaks. HCPs that co-elute in 
the product fraction can also be monitored by 2-DE which separates the proteins according to 
orthogonal principles [91]. Therefore, 2-D SDS-PAGE was used to separate the extracts of the 
transgenic plants to identify co-purifying HCPs but once again none were identified. This may 
reflect the abundance of the monoclonal antibodies in the TSP, which reduce the relative 
concentration of HCPs below the detection level of 2-D SDS-PAGE 2DGE, but the absence 
of protein spots is unlikely to be accepted by the regulators as sufficient evidence for GMP 
compliance due to the lack of quantitative data [91].  
The eluates from wild-type tobacco (N. tabacum SR1, N. tabacum K326 and N. benthamiana) 
were tested against the tobacco anti-HCP antibodies produced in rabbits. A second 1-D LDS-
PAGE experiment was carried out and the subsequent western blot is shown in Figure III-23. 
 
Figure III-23: Western blot (section II.14) of HCPs eluted from Protein A column. Lane 1: Pre-stained 
protein marker Lane 2: N. tabacum (SR1) eluate Lane 3: N. tabacum (K326) eluate Lane 4: N. benthamiana 
eluate. The primary antibody (N. tabacum and RuBisCO-depleted N. tabacum anti-HCP antibodies produced in 
rabbits) was diluted 1:1000 (3 µg mL-1) and the detection antibody (goat anti-rabbit AP) was diluted 1:5000.   
The western blot in Figure III-23 confirmed that anti-HCP antibodies produced in rabbits 
were able to detect the HCPs eluted from Protein A at pH 3.0. A major ~10 kDa protein band 
(Figure III-22B, lane 3) was not detected in the western blot (Figure III-23, lane 3). This band 
represented Protein A leaching from the column and confirmed that the anti-HCP antibodies 
did not cross-react with Protein A. The anti-HCP antibodies therefore helped to monitor HCPs 
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during downstream processing to differentiate between process-related HCPs and the product 
related impurities. It is important to remove the HCPs from the product because even a small 
amount of HCPs may reduce product efficacy or cause side effects [83, 88, 92, 96, 195]. The 
identification and characterization of HCPs is important during early process development to 
allow the introduction of polishing steps to remove known HCP impurities according to their 
known physicochemical properties, e.g. lectins that cause side effects when injected [196]. 
This approach also reduces the cost and effort required for trial and error process 
development. 
 Detection of HCPs in a purified ELP-tagged protein 
Chromatography a common method for the separation of target proteins from process-related 
and product-related impurities [144]. Variants include ion exchange chromatography (anion 
exchange or cation exchange), hydrophobic interaction chromatography, affinity 
chromatography and gel filtration/SEC which are used according to the nature of the target 
proteins and the impurities. Protein purification by chromatography can be time consuming 
and expensive [197] and non-chromatographic methods may be favorable [197-200]. One 
such method involves the use of a protein tag such the elastin-like peptide (ELP) because 
tagged protein can be separated by temperature-induced precipitation [198], [199]. 
The ELP-tagged target protein was expressed in tobacco and separated from HCPs by 
temperature-induced precipitation. The purification and HCP testing in a partially purified 
sample was carried out by Dr. Johannes Buyel (unpublished data). The presence of HCPs was 
analyzed by western blot using NtAR (Figure III-24). 
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Figure III-24: ELP-tagged fusion protein: detection of HCPs during purification using anti-HCP 
antibodies produced in rabbit against N. tabacum. (A) 1-D LDS-PAGE (section II.9) (B) Western blot 
(section II.14). Lane M: Pre-stained protein marker Lane 1: Homogenate Lane 2: Extract after depth filtration 
Lane 3: Wash Lane 4: Eluate. The green arrow (A, lane 4) shows the ~70 kDa target protein and the black 
arrow shows a degradation fragment. The anti-HCP antibodies detect (~50 kDa RuBisCO (B, lane 4, red arrow) 
and another ~130 kDa protein (B, lane 4, brown arrow).  
The majority of HCPs were removed during purification shown by Coomassie staining 
(Figure III-24A). The remaining HCPs in the product were detected by western blot using 
anti-HCP antibodies. The western blot confirmed that even after purification there were HCPs 
present that needed to be removed to improve the quality of the target protein. There was no 
cross-reactivity between the anti-HCPs antibodies and the ELP tagged target protein (Figure 
III-24B). These results further confirm the quality of the anti-HCP antibodies, which were 
developed for a generic assay but can even so detect residual HCPs after purification. This 
could provide a further strategy to achieve the clearance of biopharmaceutical products 
produced in tobacco plants for clinical trials. 
 Quantification of HCPs by ELISA during the purification of P2G12  
The Fraunhofer IME Integrated Protein Production department (IPP) has developed a robust 
purification process for P2G12 which involves filtration, Protein A chromatography and 
ceramic hydroxyapatite chromatography. An immunoassay against N. tabacum HCPs was 
used to evaluate the depletion/elimination of HCPs during the downstream processing of 
P2G12. The assay was tested on one of the P2G12 production batches (no. 140421) during 
successive processing steps and the results are shown in Table III.6.  
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Table III.6: Quantification of HCPs by direct ELISA (section II.17.1) during the downstream processing 
of P2G12. 
Sample P2G12 [mg mL-1] HCP [mg mL-1] HCP content [%] HCP/P2G12 [%] 
Protein A load 0.07 13.81 100 19700 
Protein A flow 
through 
0.001 14.25 98  
Protein A 
eluate 
3.31 0.038 0.004 1.15 
CHT load 1.88 0.024 0.005 1.34 
Final bulk 5.27 0.007 0.0003 0.14 
CHT – Ceramic hydroxyapatite chromatography  
Most of the HCPs [98%] were depleted or removed by Protein A chromatography and the 
HCPs in the eluate constituted only ~1% of the TSP. These residual HCPs were ultimately 
depleted to less than 0.2% of the TSP by hydroxyapatite chromatography, although this value 
was expected to be lower given the combination of such robust purification steps. There is a 
potential for cross-reactivity between the target protein and the anti-HCPs antibodies due the 
presence of glycans on PMPs. This was confirmed by performing a cross-reactivity test with 
P2G12 produced in tobacco and its counterpart produced in CHO cells. The anti-HCP 
antibodies showed no cross-reactivity with CHO product (Figure III-25) whereas cross-
reactivity with the heavy chains but not the light chain of the plant-derived antibody was 
confirmed providing further evidence that glycan structures were responsible. 
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Figure III-25: Cross-reactivity of 2G12 from plants and CHO cells with anti-HCP antibodies produced in 
rabbits. A. Cross-reactivity study of 2G12 from plants and CHO cells with NtAR detected by ELISA (section 
II.17.1) B. Cross-reactivity detected by western blot. Very low or no cross-reactivity was observed between 
CHO-2G12 and NtAR whereas P2G12 showed cross-reactivity by ELISA and western blot. The P2G12 heavy 
chain (HC) was detected by NtAR which confirmed that the cross-reactivity was probably due to glycosylation. 
The goat anti-rabbit detection antibody was diluted 1:5000. Optical density was measured at 405 nm.  
III.6.3.1 Reducing or eliminating cross-reactivity between P2G12 and tobacco anti-HCP 
antibodies 
Although glycosylation probably explains the cross-reactivity between anti-HCP antibodies 
and PMPs, polyclonal antibodies may also show cross reactivity with proteins because of their 
variability [201]. Cross-reactivity between target proteins and anti-HCP antibodies can 
therefore be reduced or eliminated by pre-adsorption to an immobilized target by coupling 
one protein (i.e. P2G12) to an NHS activated resin and eliminating polyclonal anti-HCPs 
antibodies that bind to it. 
P2G12 was therefore coupled to NHS-activated resin (section II.18) and the coupling 
efficiency was evaluated before and after coupling using the Bradford method (Table III.7) 
before using it to eliminate cross-reacting anti-HCPs antibodies. The pre-coupling sample and 
the supernatant after coupling were tested for total proteins using the Bradford method, as 
shown in Table III.7. 
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Table III.7: Coupling efficiency of P2G12 to NHS-activated resins. 
Sample Total protein [mg] 
P2G12 used (before coupling) 42 
P2G12 in supernatant (after coupling) 4 
 
The coupling mixture comprised 10 mL NHS-activated resin and 42 mg P2G12 (section 
II.19). After coupling, only 4 mg P2G12 could be detected in the supernatant, suggesting that 
38 mg of PG12 bound to each mL of NHS-activated resin. The coupled P2G12 resin was then 
used to capture cross-reacting anti-HCP antibodies produced in rabbits by affinity 
chromatography. The rabbit anti-HCP antibodies were passed through the P2G12 column and 
the flow through and eluate were evaluated by 1-D LDS-PAGE and western blot, as shown in 
Figure III-26.  
 
Figure III-26: Anti-HCP antibodies: polishing and evaluation by 1-D LDS-PAGE (section II.9) and 
western blot (section II.9).    Lane 1: Pre-stained protein marker Lane 2: P2G12 column flow through (silver-
stained LDS-PAGE gel) Lane 3: P2G12 column eluate (silver-stained LDS-PAGE gel) Lane 4:  P2G12 column 
flow through immunoblot (detected using a goat anti-rabbit antibody) Lane 5: P2G12 column eluate 
immunoblot (detected using a donkey anti-rabbit antibody) Lane 6: N. tabacum immunoblot (primary rabbit 
anti-HCP antibodies after P2G12 column polishing, concentration 1 µg mL-1, detected with a goat anti-rabbit 
antibody diluted 1:5000) Lane 7: 6.5 µg N. tabacum HCPs  (Coomassie-stained LDS-PAGE gel). 
The rabbit anti-HCP antibodies in the column flow through and eluate were separated by 
electrophoresis and analyzed by western blot to test the anti-HCP antibodies for binding to the 
P2G12-coupled resin. The elution fraction (Figure III-26, lane 3) showed that strongly-bound 
proteins were eluted only during the low-pH (pH 3.0) washing steps, which demonstrated that 
some of the rabbit anti-HCPs antibodies bound strongly to the coupled P2G12. These results 
were also confirmed by western blot (Figure III-26, lane 5). The P2G12 heavy and light 
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chains were detected in the elution fraction, confirming the cross-reactivity of some anti-HCP 
antibodies to P2G12 probably due to the presence of glycans. 
The efficiency of the polished rabbit anti-HCP antibodies was evaluated by western blot 
(Figure III-26, lane 6) against N. tabacum HCPs (Figure III-26, lane 7). This showed that even 
after purifying the anti-HCPs antibodies against pre-immobilized P2G12, they was still able to 
detect the majority of proteins compared to Coomassie-stained HCPs in 1-D LDS-PAGE gels 
(Figure III-26, lane 7). Eliminating the cross-reacting antibodies therefore did not 
significantly affect the ability of the anti-HCP antibodies to detect tobacco HCPs. Even 1 µg 
mL-1 of anti-HCP antibodies could detect the majority of proteins on the Coomassie-stained 
LDS-PAGE gels compared to 3 µg mL-1 required in the previous section (Figure III-6 and 
Figure III-11). Therefore, the purification of anti-HCP using pre-immobilized P2G12 does not 
affect the sensitivity of the antibodies.   
In the next experiment, an ELISA was used to confirm the elimination of cross-reactivity 
between rabbit anti-HCPs antibodies (purified against pre-immobilized 2G12) and P2G12 
itself. Three different batches of P2G12 (T090802, T131230 and T140421) were tested for 
cross-reactivity using checker board titration (section II.17.3). Wells were coated with 100 µL 
P2G12 in serial dilutions from rows 1 to 10 starting at 10 µg mL-1, whereas the polished and 
unpolished anti-HCP antibodies (100 µL per well) were serially diluted from columns A to F 
with a starting concentration of 1 µg mL-1.  Row G was used as a blank and row H was used 
as a positive control coated with polished rabbit anti-HCP antibodies (Figure III-27).  
 III. Results and discussion                                                                                              Page 68 
 
Institute for Molecular Biotechnology at the RWTH Aachen University 
PhD thesis 2015 by Zulfaquar Ahmad Arfi 
 
 
Figure III-27: Checker board titration immunoassay (section II.17.1) showing the cross-reactivity of 
unpurified rabbit anti-HCP antibodies and the same antibodies purified against immobilized 2G12 against 
P2G12. NP-1/P-1, NP-2/P-2 and NP-3/P-3 represent P2G12 batch numbers 140526, 140421 and 131021 
respectively, used to test cross-reactivity with anti-HCP antibodies. NP and P represent the unpurified and 
purified rabbit anti-HCP antibodies. For detection, a donkey anti-rabbit antibody was  diluted 1:5000. Optical 
density was measured at 405 nm. 
Purified and unpurified rabbit anti-HCP antibodies were to determine cross-reactivity against 
three different P2G12 batches. The ELISA showed that the cross-reactivity between P2G12 
and the rabbit anti-HCP antibodies was eliminated after purification against immobilized 
P2G12. The HCP levels in the P2G12 were below the direct ELISA detection threshold when 
polished anti-HCP antibodies were used for quantification. The purification of anti-HCP 
antibodies against immobilized P2G12 proved ideal for reducing or eliminating cross-
reactivity. This approach is similar to other strategies used to eliminate the cross-reactivity 
between anti-HCP antibodies and target proteins [94] although other methods such as 
blocking the cross-reacting antibodies can also be used to minimize the impact on HCP 
detection [201]. The P2G12 column produced in house became unstable after 2 weeks so 
future experiments will consider ways to improve column stability and allow multiple uses. 
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III.7  Pre-validation of direct ELISA: stability under non-GMP conditions 
As an extended part of this project, some pre-validation experiments were carried out to 
improve selected immunoassay parameters. Generally, assay validation should be performed 
according to ICH guidelines [202, 203] and under GMP conditions as an acceptance criterion. 
Validation parameters include precision, specificity, accuracy, linearity and stability. Assay 
validation may not be required for initial clinical trials [94] but when proceeding to more 
advanced stages complete validation is required to ensure FDA approval. The term pre-
validation is used here to describe parameters that, as described below, were observed and 
tested during assay development but not fully validated as per ICH guidelines. 
 HCP stability    
The standard tobacco HCPs were stored at –20oC and –80oC in single-use aliquots to avoid 
freeze–thaw stability issues [204]. They were not stable at –20oC (Supplementary Figure 
VII-6) but were stable at –80oC. The quality of the standard HCPs was determined using the 
Bradford assay for total protein content (Table III.8) and LDS-PAGE (Figure III-28) was 
carried out to check for any changes in the protein profile.  
The concentrations of N. tabacum and N. benthamiana HCPs remained unchanged according 
to the Bradford assay after 10 months (Table III.8). There were no major differences in 
protein content or protein degradation in the stored samples, and the major protein bands (~15 
and ~50 kDa) representing RuBisCO showed no sign of degradation after 10 months (Figure 
III-28). The storage of tobacco HCPs at –80°C is therefore suitable for long-term stability. 
Table III.8: Tobacco proteins: stability over 10 months when stored at –80°C. 
Sample 
30.04.2013 (initial) 
[mg∙mL-1] 
06.02.2014 (after 10 months) 
[mg∙mL-1] 
N. tabacum 25 ± 0.3  23 ± 2  
N. benthamiana 23 ± 0.7  23 ± 2  
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Figure III-28: A 1-D LDS-PAGE (Section II.9) showing the stability of tobacco proteins. Lane 1: Pre-
stained protein marker Lane 2: N. tabacum (A) and N. benthamiana (B) HCPs (initial) Lane 3: N. tabacum (A) 
and N. benthamiana (B) HCPs (after 10 months) 
 Direct ELISA linearity and working range  
The direct ELISA for N. tabacum HCPs was tested over the ranges 2.5–90 ng mL-1, 5–90 ng 
mL-1 and 5–100 ng mL-1 using in-house labeled rabbit anti-HCP antibodies diluted 1:500. A 
standard curve with a linear fit was observed over the tested concentration ranges of the 
antigen and antibody, with an R2 value of ≥0.99 and a RSD of <5%. The robustness of the 
assay was tested using different dilution strategies for the standard HCPs. One standard was 
prepared by serial dilution (section III.5.1.1, Figure III-16) and another by direct solution 
(section III.5.1.1, Figure III-17, Supplementary Figure VII-7). Both dilution strategies 
produced the linear fit with an R2 value of ≥0.99. The linearity of the assay was therefore 
unaffected by using different working ranges or dilution strategies, providing a platform that 
will be beneficial during the full validation of the immunoassay. 
 Assay reproducibility 
Assay reproducibility was tested over different antigen concentration ranges and different 
dilution strategies for the linear fit curve (section III.5.1.1). The assay was also performed 
within a day and on different days. Linearity was achieved, with an R2 value of ≥0.99 and an 
RSD of <5%. The assay was also carried out in two different laboratories (Rooms A360 and 
A361, Fraunhofer IME, Aachen). All these conditions produced a linear fit curve with an R2 
value of ≥0.99 and RSD of <5% (Figure III-29). This confirms the reproducibility and further 
supports the robustness of the direct ELISA for tobacco HCPs. 
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Figure III-29: N. tabacum direct ELISA (section II.17.1): reproducibility in different laboratories. A. 
Laboratory A360 B. Laboratory A361. The anti-HCP detection antibodies were diluted 1:500. Error bars shows 
the standard deviation (n ≥ 3). Optical density was measured at 405 nm. R2 shows the linearity of the assay. The 
graph was plotted after subtracting the blank value. 
 Detection limit (DL) and quantitation limit (QL) 
The western blots of NtHCPs and NbHCPs probed with the corresponding anti-HCP 
antibodies were able to detect as little as 1.3 ng of HCP (sections III.4.1 and III.4.2). The 
detection limit for tobacco HCPs (N. tabacum and N. benthamiana) by indirect ELISA on the 
basis of the signal-to-noise ratio was 3 ng mL-1 (section III.4.3). The DL and QL were also 
calculated for the direct ELISA as per ICH guidelines [205] using the formula shown below. 
 
The DL for N. tabacum anti-HCP antibodies based on the calibration curve representing 2.5–
90 ng mL-1 of antigens (Figure III-17) was 1.8 ng mL-1 and the QL was 5.6 ng mL-1. Using the 
calibration curve representing 5–90 ng mL-1 of antigens, the DL was 2.49 ± 0.02 (n = 3) and 
the QL was 7.55 ± 0.08 (n = 3). The pre-validation curve for LOD and LOQ are provided in 
Supplementary Figure VII-7. The DL for N. benthamiana anti-HCP antibodies based on the 
calibration curve representing 2.5 – 90 ng mL-1 of antigens (Figure III-18) was 2.3 ng mL-1 
and the QL was 7.1 ng mL-1. The direct ELISA for tobacco HCPs therefore achieved a 
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sensitivity of ~2 ng mL-1. It is still possible that the sensitivity may be increased by using the 
more sandwich ELISA method. 
 Spiked HCP recovery  
In a spiked recovery experiment, affinity-purified P2G12 (250 ng mL-1) in the presence of 
0.9% (w/v) sodium chloride was spiked with HCPs at concentrations ranging from 0–90 ng 
mL-1. A direct ELISA was then used to recover the spiked HCPs (Table III.9). 
Table III.9: Spiked HCP recovery in the presence of P2G12 and 0.9% (w/v) NaCl.  
Sample HCPs spiked [ng mL-1] HCP recovered [%] 
0.9% NaCl 50 92 
0.9% NaCl 90 84 
P2G12 [250 ng mL-1] 0 0 
P2G12 [250 ng mL-1] 10 65 
P2G12 [250 ng mL-1] 50 116 
P2G12 [250 ng mL-1] 90 103 
 
Each sample was tested in duplicate. Spiking normal saline buffer with 50 and 90 ng mL-1 
HCPs resulted in the recovery of ~92% and ~84% of the HCPs, respectively. In the presence 
of 250 ng mL-1 P2G12, spiking with 10 ng mL-1 HCPs resulted in ~65% recovery, whereas 
spiking with 50 and 90 ng mL-1 HCPs resulted in the recovery of ~116% and ~103% of the 
HCPs, respectively. The low recovery with the smaller spike was improved by repeating the 
experiment with more careful pipetting. The results showed that HCPs can be detected and 
measured in the presence of the monoclonal antibody P2G12 produced in tobacco plants. 
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IV Conclusion and outlook 
IV.1 Preparation of antigens (tobacco HCPs) for immunization and the 
evaluation of individual bleeds  
Antigens for the immunization of animals were prepared in the form of total soluble protein 
(TSP) extracts from the leaves of tobacco plants (N. tabacum and N. benthamiana) as 
previously described [145]. TSP extracts from both species were quantified using the 
Bradford method with BSA as the standard. The concentration thus obtained may be 
misleading and a standard protein derived from plants, e.g. RuBisCO, may be more 
appropriate for the quantification of tobacco TSP.    
A general feature of protein extracts from photosynthetically active plants is the abundance of 
RuBisCO, a protein which accounts for 30–50% of the TSP [102, 206]. The large amount of 
one particular protein in a complex mixture may compromise the immune response against 
other (less abundant) proteins during immunization due to antigen 
competition/immunosuppression. To avoid such phenomena, we decided to reduce the 
amount of RuBisCO in the antigen preparations to minimize its effect on other less abundant 
proteins. A method was adapted for RuBisCO depletion by PEG precipitation [117] for final 
antigen preparation and ~90% of RuBisCO was removed (Section III.1.2) without the 
significant loss of other proteins. PEG precipitation for RuBisCO depletion is an economical 
and time saving procedure which has already been applied successfully in the context of plant 
proteomics. For example, PEG precipitation increased the exposure of less abundant proteins 
which could not be detected in the presence of RuBisCO [116, 117]. Similarly, RuBisCO 
depletion from TSP exposes the less abundant proteins during immunization and a 
corresponding immune response can be expected. PEG precipitation is useful for the depletion 
of abundant proteins (i.e. RuBisCO) from the mixture but conditions need to be optimized for 
each particular application.  
The removal of endotoxins from antigen preparations is a prerequisite before immunization 
because endotoxins can cause fatal septic shock when injected into animals [106, 107]. 
Protein extracts from wild-type tobacco plants contain only limited amounts of endotoxins, 
which can be removed efficiently by affinity chromatography techniques, e.g. using 
Polymyxin B agarose [167] or EndoTrap Blue columns [174] (Section III.1.3). However, 
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these methods alone were not sufficient to remove the large amounts of endotoxins present in 
extracts from Agrobacterium-infiltrated tobacco leaves, in particular due to capacity 
limitations, and a complementary step using endotoxin-removal filters was required. The 
FiberFlo EN filtration method was able to reduce the endotoxin level by ~98%, and further 
reduction was then achieved using Polymyxin B agarose or EndoTrap blue columns (Section 
III.1.3). After reducing the endotoxin content of the extracts to a permissible level, the 
antigens were ready for immunization. The methods described in this thesis for the removal of 
endotoxins from tobacco HCPs can also be applied to remove endotoxins from 
biopharmaceutical proteins during the final polishing steps of downstream processing [123, 
167, 174]. 
RuBisCO-depleted and untreated tobacco leaf extracts were used to immunize rabbits and 
goats once the endotoxin-removal step was complete. Rabbits and goats are commonly used 
for antibody production because they require minimal handling and provide enough antisera 
for immunoassay development [161]. The protocols for immunization were discussed and 
finalized with an external service provider whose facility was used for the generation of 
polyclonal antisera against tobacco HCPs. None of the immunized animals showed any side 
effects or died during the immunization period, confirming the quality of the antigen 
preparations.  
One-dimensional western blotting and indirect ELISA were used to characterize the reactivity 
of the anti-HCP antisera. Individual bleeds were tested for the titer of anti-HCP antibodies. 
Densitometric analysis confirmed a satisfactory immune response against HCPs from the 
second bleed onwards (NtHCPs, NtRdHCPs and NbHCPs) (Sections III.2 and III.3.1.2). 
However, there was not much difference between the fourth bleed and the final bleed 
suggesting that the protocol can be shortened. The comparison of protein band patterns within 
individual bleeds showed that for many protein bands the signal strength differed significantly 
between the western blot and corresponding SDS-PAGE gels. This shows the different 
immunogenicity or immune response towards different proteins from N. tabacum (SR1) and 
N. benthamiana in rabbits. The difference in titer did not affect the quality of the antisera, 
which detected the majority of HCPs. 
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IV.2 Characterization of anti-HCP antibodies 
The impact of antigen preparation by different methods was shown by characterizing the 
polyclonal anti-HCP antibodies by 1-D and 2-D western blots (Sections III.2 and III.3.1). The 
polyclonal anti-HCP antibodies raised against NtHCPs, NtRdHCPs and NbHCPs showed a 
wide range of HCP coverage (Section III.2.1). These experiments showed the advantages of 
anti-HCP antibodies generated against NtRdHCPs compared with non-depleted NtHCPs, i.e. 
more intense bands were present on the 1-D western blot with antibodies against NtRdAR 
rather than NtHCPs (Section III.2.1) and extra proteins spots were present on the 2-D western 
blot using NtRdAR (Section III.2.1). However, other protein spots were missing from the 2-D 
western blot using NtRdAR. Therefore, a combination of extracts should maximize the 
coverage of the immune response and increase the number of HCPs that can be detected. 
Combining non-depleted and RuBisCO-depleted extracts for maximum HCP coverage is a 
straightforward approach that avoids antigenic competition, resulting in an immune response 
against even scarce HCPs. The method is thus an improvement over previously suggested 
procedures such as cascade immunization [99] or passive pre-immunization [100], which 
require more sophisticated and more cumbersome procedures. The analysis of HCPs 
separated by SDS-PAGE using anti-HCP antibodies is standard industry practice that is 
usually accepted by the regulators and shows the coverage of HCPs by the corresponding 
antibodies.    
Initial cross-reactivity was observed within the same batch of anti-HCP antibodies (rabbit-
rabbit) as well as between anti-HCP antibodies raised in goats and rabbits. This was 
minimized in the case of rabbit-rabbit antibodies by checker board titration (Section III.5.4) 
whereas this attempt failed to minimize inter-species cross-reactivity (goat-rabbit). Another 
strategy was tested to eliminate inter-species cross-reactivity, i.e. the coupling of the goat 
anti-HCP antibodies to a solid matrix followed by the affinity-based removal of cross-reacting 
rabbit anti-HCP antibodies. In initial experiments, goat anti-HCP antibodies were successfully 
coupled to NHS-activated resin although the coupling was not stable when a low-pH buffer 
was used for elution. Further optimization is required to avoid the leaching of bound 
antibodies from resin. Once this has been achieved, the procedure can be used to eliminate 
cross-reactivity between the two panels of anti-HCP antibodies as a pre-requisite for an 
efficient sandwich ELISA. 
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IV.3 Assay development  
The anti-HCP antibodies generated against NtHCPs, NtRdHCPs and NbHCPs were able to 
detect as little as 1.3 ng of HCP in 1-D western blots (Sections III.4.1 and III.4.2).  
A quantitative direct ELISA was set up to detect NtHCPs and NbHCPs and different 
parameters required for assay validation such as LOD and linearity were evaluated (Section 
III.4). The assays were linear over a wide range of standard HCP concentrations (2.5–90 ng 
mL-1) and were able to detect as little as ~2 ng mL HCP (Sections III.5.1.1 and III.7.4). The 
sensitivity achieved by this immunoassay confirmed the quality of the anti-HCP antibodies 
and the assay setup. Initial validation under non-GMP conditions confirmed assay linearity 
and reproducibility. There was no change in the linearity under different working conditions 
such as switching to another laboratory. The assay setup will facilitate the design of 
chromatography methods for the purification of plant-derived pharmaceutical proteins by 
allowing rapid testing for the presence or absence of HCPs after each process step. It will also 
expand the set of quality control assays that can routinely be used to assess and monitor the 
quality of APIs produced in plants.  
The upper limit for HCPs considered safe by the scientific community is ≤ 100 ng/mg, 
although no upper limit is defined by the regulatory authorities [83, 92, 207]. The evaluation 
of HCPs is carried out on a case-by-case basis on the mutual understanding of the 
manufacturer and regulatory authority. The removal of HCPs depends on the purification 
processes, e.g. in the well-established manufacturing processes for monoclonal antibodies 
HCP levels can be reduced to 1 ng/mg or lower. The HCP assay is proposed by regulatory 
authorities as part of release testing procedure, but in one case (natalizumab) EMA accepted 
the removal of HCPs from release testing results showing that more than 30 batches contained 
low HCP levels. HCP assays are sensitive enough to detect the broad range of HCPs but it 
may not detect proteins below this limit or non-immunogenic HCPs. Additional sensitive 
assays are required for the identification and characterization of such proteins, e.g. mass 
spectrometry identifies individual proteins whereas HCP assays may fail to differentiate them. 
Any changes to the purification process may change the HCP elution profile, demanding 
additional evaluation and validation of the HCP assay. Quality by design (QbD) approaches 
can play an important role in the evaluation of HCP assays. Generic assays are accepted only 
during initial clinical trials, whereas process-specific HCP assays are required for advanced 
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clinical trials. The HCP in-process control data must be provided in the clinical trial 
documentation package [208].  
The current assay setup will provide a benchmark for full validation under GMP conditions 
following complete ICH guidelines. At this point, the ELISA is not fully validated but it is 
scientifically sound. For early-phase clinical trials, the full validation of analytical methods is 
not expected by the competent authorities, and the HCP ELISA method described in this 
thesis will deliver a valuable addition to the spectrum of analytical methods for the QC-testing 
of plant-derived pharmaceutical proteins. 
IV.4 Applications 
The assay setup described above was successfully deployed during bioprocess development at 
the IME where it was used to detect and quantify HCPs in the process feed stream of the 
biopharmaceutical product P2G12 (Section III.6.3). As an alternative step, the feed stream can 
be tested for the presence of RuBisCO using monoclonal antibodies which are more specific 
than polyclonal antisera. This also provides a bench mark for the removal of HCPs during 
downstream processing. The anti-HCP antibodies were able to detect the HCPs eluted during 
purification and showed no cross-reactivity with the target protein (Sections III.6.1 and 
III.6.2).  
The generic (i.e. not product-specific) tobacco HCP ELISA can be used for biopharmaceutical 
process development by quantitatively testing the ability of individual unit operations to 
reduce HCP levels as well as the QC release testing of the finished API. However, the anti-
HCP antibodies may not detect less-immunogenic and non-immunogenic impurities, for 
which orthogonal analytical methods would be required [209, 210]. The assay provides a 
means to introduce the QbD approach during assay validation, which is already accepted by 
the industry as a way to improve the quality of biopharmaceutical products [80, 81, 211, 212].   
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V Summary  
Recombinant proteins have been produced in plants for decades but regulatory approval 
(marketing authorization) for a recombinant biopharmaceutical protein produced in a plant-
based expression system was only achieved in May 2012. This has opened the door for the 
production of biopharmaceutical proteins in plants, but the development of a comprehensive, 
standardized set of analytical methods is still underway. The quantitative analysis of HCPs in 
drug substances and drug products is a key regulatory requirement for all biopharmaceuticals 
because this ensures HCPs are reduced to acceptable levels in the final product (typically 10–
100 ppm), and qualitative and quantitative immunoassays are required to achieve such 
sensitivity. The aim of the work described in this thesis was to develop a generic 
immunoassay for the quantification of tobacco-specific HCPs as a counterpart for the 
commercially available assays for more-established expression systems such as CHO cells 
and E. coli. 
The generation of polyclonal antisera against the majority of tobacco HCPs is prevented by 
the presence of RuBisCO. The first part of this thesis describes a rapid and inexpensive 
method to achieve the depletion of RuBisCO from tobacco extracts using PEG 4000. The 
other major challenge was to produce the endotoxin-free antigens before immunization. The 
low endotoxin load was easily removed from wild-type tobacco plants (N. tabacum), which 
are used for stable expression, using Polymyxin B agarose. However, the extracts of 
agroinfiltrated tobacco plants (N. bethamiana), which are used for transient expression, 
contain much higher endotoxin levels and a two-step process was required, involving a 
FiberFlo EN filter to remove most endotoxins followed by Polymyxin B agarose or EndoTrap 
blue columns to remove residual amounts. In the second part of the thesis, unpurified and 
purified antibodies were tested against their corresponding antigens by 1-D and 2-D western 
blot and ELISA. Western blots of N. tabacum and N. benthamiana HCPs confirmed wide 
coverage by the anti-HCP antibodies, although antibodies generated against RuBisCO-
depleted extracts and non-depleted extracts each detected unique spots. In the third part of the 
thesis, an ELISA was set up for N. tabacum and N. benthamiana HCPs allowing qualitative as 
well as quantitative detection. Finally, this immunoassay setup was applied in the downstream 
processing of a plant-derived biopharmaceutical to confirm the log reduction in HCP levels 
achieved during different process steps. The anti-HCP antibodies detected HCPs which had 
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bound and eluted during protein A affinity chromatography, confirming that the assay was 
suitable for deployment during process development. 
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V Summary (German version) 
Rekombinante Proteine werden bereits seit mehreren Jahrzehnten in Pflanzen hergestellt, 
doch erst im Mai 2012 erfolgte die erste behördliche Zulassung (Marktzulassung) eines 
solchen Produktes. Obwohl dies den Weg für die Produktion von biopharmazeutischen 
Proteinen bereitet hat, befindet sich die Etablierung von einheitlichen Analysemethoden noch 
in der Entwicklung. Eine quantitative Analyse der in einem pharmazeutischen Produkt 
enthaltenen Wirtsproteine (engl.: host cell proteins, HCPs) wird von regulatorischer Seite 
erwartet, um nachzuweisen, dass diese erfolgreiche auf ein Niveau von 10-100 ppm 
abgereichert wurden. Für diese Analysen mit solcher Sensitivität sind qualitative und 
quantitative Immunassays erforderlich. In der vorliegenden Arbeit sollten solche Tabak-
spezifischen Assays als Gegenstück zu kommerziell erhältlichen Produkten für E. coli und 
CHO Zellen entwickelt werden. 
Die Erzeugung von polyklonalen Seren, die den Großteil der Tabak HCPs abdecken, wird 
jedoch durch die Gegenwart von RuBisCO verhindert, welche daher im ersten Teil dieser 
Arbeit durch eine schnelle und kostengünstige Fällung mit PEG abgereichert wurde. Die 
größte Herausforderung dabei war es, den finalen Extrakt von Endotoxinen zu befreien, so 
dass eine Immunisierung möglich wurde. Während bei Wildtyp Tabakpflanzen (N. tabacum) 
ein einziger Schritt mit Polymyxin B agarose ausreichte, war aufgrund der Infiltration mit A. 
tumefaciens ein zweistufiger Prozess bestehen aus FiberFlo EN und Polymyxin B bzw. 
EndoTrap blue bei N. benthamiana erforderlich. Im zweiten Teil der Arbeit wurden Seren und 
gereinigte Antikörper in 1-D und 2-D Western Blots, sowie durch ELISA hinsichtlich der 
Detektion der zugehörigen Antigene charakterisiert. Für alle Antikörper konnte gezeigt 
werden, dass sie eine Vielzahl der HCPs detektieren, allerdings erkannten die verschiedenen 
Präparationen (Regulär und RuBisCO-abgereichert) unterschiedliche Untergruppen von 
HCPs. Im dritten Teil der Arbeit wurde ein ELISA zur qualitativen und quantitativen 
Detektion von N. tabacum und N. benthamiana HCPs etabliert. Dieser Test wurde letztlich 
auf die Produktreinigung eines pflanzlich hergestellten Biopharmazeutikums angewandt und 
dadurch die log-Reduktion der HCPs nachgewiesen. Der Test konnte zudem HCPs 
nachweisen, die im Protein A Reinigungsschritt gebunden hatten, was seine Nützlichkeit bei 
der Prozessentwicklung unterstreicht. 
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VII Appendix 
VII.1 List of equipment and consumables 
Name Type/Use Manufacturer 
–20oC premium –20oC freezer Liebherr, Germany 
 Phytotron Fraunhofer IME, Germany 
0.2 µm filter Filter Carl Roth GmbH, Germany 
0.2 + 0.45 µm Filter Sartorius, Germany 
0.5, 1.5 and 2.0 ml Reaction tubes Sarstedt, Germany 
15 and 50 ml Reaction tubes Greiner Bio-One, Austria 
2.0 ml cryotube Cryo tube Carl Roth GmbH, Germany 
96 well flat bottom plate 96 well plate Greiner Bio-One, Austria 
Akta explorer Chromatographic device  
Akta purifier Chromatographic device  
Allegra 25R Centrifuge Beckman Coulter, CA, USA 
Biophotometer Photometer Eppendorf, Germany 
BioWizard Sterile bench Kojair, Finland 
BP 121 S Scale Sartorius, Germany 
BP 610 Scale Sartorius, Germany 
CanoScan 5600F Scanner Canon, Thailand 
Cellstart 96 well plate Greiner Bio-One, Austria 
Centrifuge 5415D Centrifuge Eppendorf, Germany 
Commercial Blender Blender Warring, CT, USA 
Cond 315i Conductometer WTW, Germany 
Forma –86C ULT freezer –80oC freezer 
Thermo Fisher Scientific, 
MA, USA 
Innova 4230 Incubator/shaker 
New Brunswick Scientific, 
CT, USA 
KMO 2 basic Stirrer IKA, Germany 
M-Power Scale Sartorius,  Germany 
Mikro 220R Centrifuge Hettich, Germany 
MiniGyroRocker SSM3 Rocker Barloworld Scientific, UK 
MiniSubCell GT Gel electrophoresis chamber Bio-Rad, CA, USA 
MiraCloth 1R Filter tissue Merck, Germany 
N816 Vacuum pump KNF, Germany 
Nitrocellulose membrane Blotting membrane Life technologies, 
pH 340i pH meter Peqlab, Germany 
PowerPac300 DC source Bio-Rad, CA, USA 
PowerPacBasic DC source Bio-Rad, CA, USA 
Premium Refrigerator Liebherr, Germany 
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Name Type/Use Manufacturer 
PVDF membrane Blotting membrane Millipore, MA, USA 
ReadyStrips IPG Strip IEF Bio-Rad, 
RTC basic Stirrer Liebherr, Germany 
RZR1 Stirrer Heidolph, Germany 
Sartopore 2 150 Filter 
Sartorius-Stedim, Goettingen, 
Germany 
Sentix 41 pH electrode WTW, Germany 
Vivaflow 50 Cross-flow device Sartorius, Germany 
Vivaflow 200 Cross-flow device Sartorius, Germany 
Synergy HT 96-well spectrometer BioTek, VT, USA 
Tecan Infinite 200M 96-well spectrometer Mannedorf, Switzerland 
Thermomixer compact Temperature controlled Eppendorf, Germany 
Trans/Blot cell Blotting chamber Bio-Rad, USA 
Varioklav Autoclave H+P, Germany 
Vivaspin 15R Ultrafiltration 
Sartorius, Goettingen, 
Germany 
Vortex-Geni2 Vortex Scientific Industries, IL, USA 
Whattman paper Blotting paper Whattman Inc., USA 
XCell Sure lock Electrophoresis chamber Invitrogen, CA, USA 
XCell II Blot module Invitrogen, CA, USA 
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VII.2 List of chemicals and reagents 
Name Type/Use Manufacturer 
ABTS powder & tablet Buffer component Roche, Mannheim, Germany 
Acetosyringone Phytohormone  Duchefa, The Netherland 
Ampicillin Antibiotic  Carl Roth GmbH, Germany 
Albumin Fraction V Blocking Carl Roth GmbH, Germany 
Carbenicillin Antibiotic  Duchefa, The Netherland 
Di-potassium hydrogen 
phosphate 
Buffer component Carl Roth GmbH, Germany 
Di-sodium hydrogen phosphate Buffer component Carl Roth GmbH, Germany 
Donkey anti-goat H+L AP Antibody  Sigma-Aldrich, USA 
Donkey anti-rabbit H+L AP Antibody  Sigma-Aldrich, USA 
DTT Buffer component Carl Roth GmbH, Germany 
Endotoxin-specific buffer Blocking buffer Osaka, Japan 
Ethanol Solution component Carl Roth GmbH, Germany 
Goat alpha-rabbit H+L AP Antibody Jackson, UK 
Iodoacetamide Buffer component Sigma-Aldrich, Germany 
Kanamycin Antibiotic Duchefa, The Netherland 
LAL QCL-1000 Endotoxin kit Lonza, MD, USA 
Methanol Solution component Carl Roth GmbH, Germany 
Murashige & Skoog salts Solution component Duchefa, The Netherland 
NHS-activated Sepharose 4FF Protein coupling Uppsala, Sweden 
NuPAGE MES Buffer component Invitrogen, CA, USA 
Page ruler pre-stained Protein marker Thermo Scientific, Lithuania 
Pierce LAL Chromogenic Endotoxin  
Thermo Fisher Scientific, 
Rockford, USA 
Polyethylene glycol Buffer component 
Applichem, Darmstadt, 
Germany 
Potassium chloride Buffer component Carl Roth GmbH, Germany 
Potassium dihydrogen 
phosphate 
Buffer component Carl Roth GmbH, Germany 
Rabbit anti-goat H+L AP Antibody  Sigma-Aldrich, USA 
Rifampicin Antibiotics Duchefa, The Netherland 
Sodium acetate Buffer component Carl Roth GmbH, Germany 
Sodium chloride Buffer component Carl Roth GmbH, Germany 
Sodium dihydrogen phosphate Buffer component Carl Roth GmbH, Germany 
Sodium disulfite Antioxidant  Carl Roth GmbH, Germany 
Sodium hydroxide Base  Carl Roth GmbH, Germany 
Starting Block Blocking buffer Thermo Fisher Scientific, 
Sucrose Buffer component Duchefa, The Netherland 
SYPRO Ruby Staining buffer Invitrogen, Paisley, UK 
Tri-flouroacetic acid Acid  Carl Roth GmbH, Germany 
Tris base Buffer component Carl Roth GmbH, Germany 
Tris-HCl Buffer component Carl Roth GmbH, Germany 
Trisodium phosphate Buffer component Carl Roth GmbH, Germany 
Tween-20 Non-ionic detergent Carl Roth GmbH, Germany 
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VII.3 List of buffers 
 Name            Component                 Final concentration [-]         pH 
2-fold infiltration medium  Sucrose   0.3       [mol∙L-1]  5.6 
     Glucose   0.02     [mol∙L-1] 
           Murashige & Skoog salts 0.86%  [w/v]  
    Acetosyringone  0.0002 [mol∙L-1] 
 
AP buffer    Tris    0.1       [mol∙L-1]  9.6 
     NaCl    0.1       [mol∙L-1] 
            MgCl2    0.005   [mol∙L-1] 
 
Blotting buffer  Tris    0.025   [mol∙L-1]  8.2 
    Glycine   0.192   [mol∙L-1] 
            Methanol    20%    [v/v] 
 
Extraction buffer   Na2HPO4   0.05     [mol∙L-1]  8.0 
     NaCl    0.25     [mol∙L-1] 
            Na2S2O5    0.01    [mol∙L-1] 
 
HBS-EP+    HEPES   0.01     [mol∙L-1]  7.4 
     EDTA   0.003   [mol∙L-1] 
            NaCl     0.15    [mol∙L-1] 
    Tween-20    0.05% [w/v] 
 
MES buffer    MES    0.05     [mol∙L-1]   7.3 
     Tris    0.05     [mol∙L-1] 
            EDTA    0.03%  [w/v] 
    SDS    0.1%    [w/v] 
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Name             Component                       Final concentration [-]  pH 
PBS (-T)    Na2HPO4   0.01     [mol∙L-1]  7.4 
     KH2PO4   0.0017 [mol∙L-1] 
             NaCl    0.137   [mol∙L-1] 
     KCl    0.0027 [mol∙L-1] 
     Tween-20   0.05%  [w/v] 
 
Yeast extract broth   Beef extract   0.5%    [w/v]   7.0 
         (YEB)    Yeast extract   0.1%    [w/v] 
             Peptone   0.5%    [w/v] 
     Sucrose   0.015   [mol∙L-1] 
     MgSO4   0.002   [mol∙L-1] 
 
ELISA coating buffer  Na2CO3    0.015   [mol∙L-1]  9.6 
    NaHCO3       0.035   [mol∙L-1] 
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VII.4 Supplementary data 
 RuBisCO depletion by sodium phytate/calcium chloride precipitation  
 
Figure VII-1 (Supplementary): RuBisCO depletion (section II.6.1) from N. tabacum using sodium 
phytate/calcium chloride. A. Lane 1. Pre-stained protein marker Lane 2. N. tabacum homogenate (HCPs) 
Lane 3. N. tabacum HCPs (supernatant) post-incubation with sodium phytate/calcium chloride mixture Lane 4. 
N. tabacum HCPs (precipitate) post-incubation with sodium phytate/calcium chloride mixture. B. Percentage of 
RuBisCO depletion by sodium phytate/calcium chloride. Values for 5 mM and 10 mM are the average of two (n 
= 2) and three (n = 3) respectively. Non-target proteins removed in the precipitate are marked by green arrows. 
Error bars indicate the standard deviation. 
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 Individual bleed characterization following NtHCPs immunization (rabbits) 
 
Figure VII-2 (Supplementary): Immunoreactivity (1-D western blots) (section II.14) of N. tabacum (SR1) 
HCPs against corresponding anti-HCP antiserum. Lane 1: Pre-stained protein marker Lane 2: N. tabacum 
homogenate (LDS-PAGE) Lane 3: N. tabacum antiserum (bleed 1) Lane 4: N. tabacum antiserum (bleed 2) 
Lane 5: N. tabacum antiserum (bleed 3) Lane 6: N. tabacum antiserum (bleed 4) Lane 7: N. tabacum antiserum 
(final bleed) Lane 8: N. tabacum antiserum (bleed pool) Lane 9: Pre-stained protein marker. Proteins were 
detected with a goat anti-rabbit antibody diluted 1:5000. Each lane contained 6.5 µg HCPs. The brown arrow in 
lane 6 shows that a specific antibody only appeared in bleed 4. The orange arrow indicates the development and 
maturation of an antibody binding to 40-kDa protein. Anti-HCP antibodies covered >90% of the HCPs according 
to 1-D western blot analysis.  
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 Individual bleed characterization following NtRdHCPs immunization (rabbits) 
 
Figure VII-3 (Supplementary): Immunoreactivity (1-D western blots) (section II.14) of RuBisCO-depleted 
N. tabacum (SR1) HCPs against corresponding anti-HCP antiserum. Lane 1: Pre-stained protein marker 
Lane 2: N. tabacum homogenate (LDS-PAGE) Lane 3: N. tabacum RuBisCO-depleted antiserum (bleed 1) 
Lane 4: N. tabacum RuBisCO-depleted antiserum (bleed 2) Lane 5: N. tabacum RuBisCO-depleted antiserum 
(bleed 3) Lane 6: N. tabacum RuBisCO-depleted antiserum (bleed 4) Lane 7: N. tabacum RuBisCO-depleted 
antiserum (final bleed) Lane 8: N. tabacum RuBisCO-depleted antiserum (bleed pool) Lane 9: Pre-stained 
protein marker. Proteins were detected with a goat anti-rabbit antibody diluted 1:5000. Each lane contained 6.5 
µg HCPs. The orange arrow indicates the development and maturation of an antibody only after the second bleed 
whereas the remaining protein bands are clearly visible from second bleed onwards. Anti-HCP antibodies 
covered >90% of the HCPs according to 1-D western blot analysis.  
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 Individual bleed characterization following NbHCPs immunization (rabbits) 
 
Figure VII-4 (Supplementary): Immunoreactivity (1-D western blot) (section II.14) of N. benthamiana 
(agroinfiltrated) HCPs against corresponding anti-HCP antiserum. Lane 1: Pre-stained protein marker 
Lane 2: N. benthamiana antiserum (bleed 1) Lane 3: N. benthamiana antiserum (bleed 2) Lane 4: N. 
benthamiana antiserum (bleed 3) Lane 5: N. benthamiana antiserum (bleed 4) Lane 6: N. benthamiana 
antiserum (final bleed) Lane 7: N. benthamiana antiserum (bleed pool) Lane 8: N. benthamiana homogenate 
(LDS-PAGE). Each lane contained 6.5 µg HCPs. Black arrow in lane 6 and orange arrow in lane 7 indicate 
bands only visible in the final bleed. Brown arrows indicate the dominant protein band in the western blot. 
Proteins were detected with a goat anti-rabbit antibody diluted 1:5000. Anti-HCP antibodies covered >90% of 
the HCPs according to 1-D western blot analysis.  
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 Characterization of unpurified antiserum generated against NtHCPs, 
NtRdHCPs and NbHCPs 
               
 
Figure VII-5 (Supplementary): Immunoreactivity (indirect ELISA) (section II.17.1) of N. tabacum HCPs 
against the corresponding anti-HCP antiserum. The x-axis represents the antiserum dilutions and the y-axis 
shows the OD405nm. N represents the N. tabacum, RuBisCO-depleted N. tabacum and N. benthamiana antisera 
and pre-immune initial dilution (N = 1:1000). Binding was detected using an HRP-conjugated goat anti-rabbit 
antibody diluted 1:5000 dilutions. Error bars show the standard deviation (n≥3). The titers for the N. tabacum 
and RuBisCO-depleted N. tabacum antisera were 1:256,000 whereas for the N. benthamiana antiserum it was 
1:32,000. 
 NtHCPs stability  
 
Figure VII-6 (Supplementary): Stability of NtHCPs at –20°C determined by 1-D LDS-PAGE (section 
II.9). Lane 1. Pre-stained protein marker Lane 2. NtHCPs LDS-PAGE (04.07.2012) Lane 3. NtHCPs LDS-
PAGE after ~5 months (12.12.12). Changes in the protein profile resulted from the degradation of proteins over 
time.   
A B 
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 Pre-validation of direct ELISA curve for linear reproducibility, LOD and LOQ 
(N. tabacum) 
 
Figure VII-7 (Supplementary): N. tabacum direct ELISA (section II.17.1): LOD and LOQ validation 
standard curve. The anti-HCP detection antibody was diluted 1:500. Error bars show the standard deviation 
(n ≥ 3). Optical density was measured at 405 nm. R2 confirmed the linearity of the assay. The graph was plotted 
after subtracting the blank value. 
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 Proteins in the N. tabacum extract before and after RuBisCO depletion 
Table VII.1: MS analysis of N. tabacum extracts before and after RuBisCO depletion following separation 
by 1-D LDS-PAGE. Highlighted proteins in the RuBisCO-depleted extract were not detectable (green 
color) in the presence of RuBisCO while proteins marked in red were not detected in RuBisCO-depleted 
extract. 
Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
 Extract N. tabacum (SR1)   
NbS00002522g0001.1 14 3 3 protein A 28.8 3 
 
PMGI_TOBAC 
 
2,3-Bisphosphoglycerate-independent 
phosphoglycerate mutase (Nicotiana tabacum) 61 2 
NbS00017361g0009.1 
5-methyltetrahydropteryltriglutamate- 
homocystein methyltransferase 84.8 6 
NbS00013023g0001.1 Aminomethyltransferase, mitochondrial 44.2 3 
NbS00019305g0027.1 ATP synthase subunit beta, mitochondrial 59.7 3 
giǀ115473 
Carbonic anhydrase, chloroplastic (Nicotiana 
tabacum) 
34.5 4 
giǀ1705613 Catalase isozyme 1 (Nicotiana tabacum) 56.8 7 
NbS00005183g0002.1 Chaperonin 60 beta subunit 64.8 2 
NbS00029684g0026.1 Chloroplast heat shock protein 70-1 75.2 2 
NbS00017751g0013.1 Cysteine synthase 34.2 2 
NbS00001281g0003.1 
Ferredoxin dependent glutamate synthase, 
chloroplastic 
49.3 2 
NbS00020069g0017.1 
Ferredoxin dependent glutamate synthase 1, 
chloroplastic 
126.4 5 
NbS00028064g0012.1 Fructose bisphosphate aldolase 42.8 9 
NbS00022684g0008.1 
Glycine dehydrogenase decarboxylating, 
mitochondrial 
128 5 
NbS00009983g0008.1 Heat shock cognate 70 kDa protein 2 41.9 4 
NbC25737543g0001.1 Malate dehydrogenase 29.8 2 
NbS00030132g0003.1 NADP binding Rossmann fold 33.6 4 
NbS00022693g0009.1 Nitrite reductase 84.8 2 
NbS00017066g0003.1 Oxalate oxidase germin 171 21.6 2 
NbS00010498g0007.1 Oxygen evolving enhancer protein 3 24.2 2 
NbS00005125g0015.1 Peroxisomal S 2 hydroxy acid oxidase 38.8 4 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00018854g0005.1 Phosphoenolpyruvate carboxylase 1 109.5 4 
NbS00020603g0012.1 Phosphoglucomutase, cytoplasmic 64.6 4 
giǀ2499497 Phosphoglycerate kinase (Nicotiana tabacum) 50.1 9 
giǀ194396261 Plastid transketolase (Nicotiana tabacum) 80 5 
NbS00001859g0006.1 Phosphoglycerate kinase 58.6 9 
RBL_NICSY 
Ribulose bisphosphate carboxylase large chain 
(Nicotiana sylvestris) 
52.9 24 
NbS00027201g0002.1 
Ribulose bisphosphate carboxylase small chain, 
chloroplastic 
20.6 8 
NbS00020031g0005.1 S adenosyl L homocysteine hydrolase 53.1 3 
NbS00027243g0010.1 Sedoheptulose bisphosphatase 30.8 3 
NbS00019758g0008.1 Serine glyoxylate aminotransferase 43.9 4 
NbS00027670g0006.1 Serine hydroxymethyltransferase 59 7 
NbS00008412g0009.1 Transketolase 1 86.2 11 
RuBisCO-depleted extract of N. tabacum 
PMGI_TOBAC 
2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase (Nicotiana tabacum) 
61.0 2 
NbS00017361g0009.1 
5-methyltetrahydropteroyltriglutamate-
homocysteine methyltransferase 
84.8 11 
NbS00013344g0009.1 31 kDa RNA binding protein 34.5 2 
NbS00011955g0007.1 Aldose 1 epimerase 31.7 2 
NbS00035335g0017.1 Calreticulin 2 calcium binding protein 47.3 2 
giǀ115473 
Carbonic anhydrase, chloroplastic (Nicotiana 
tabacum) 
34.5 8 
NbS00013764g0007.1 Catalase isozyme 1 52.7 7 
NbS00005183g0002.1 Chaperonin 60 beta subunit 64.8 12 
NbS00009495g0011.1 
Dihydrolipoyl dehydrogenase 1, 
mitochondrial 
56.8 2 
NbS00000250g0010.1 Enolase 56.6 2 
NbS00020069g0017.1 
Ferredoxin dependent glutamate synthase 1, 
chloroplastic 
125.4 15 
NbS00001281g0003.1 
Ferredoxin dependent glutamate synthase, 
chloroplastic 
49.3 6 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00017344g0018.1 Glutamine synthetase 47.4 4 
NbS00018339g0012.1 Glycine cleavage system H protein 1 17.5 2 
NbS00022684g0008.1 
Glycine dehydrogenase decarboxylating, 
mitochondrial 
128        7 
NbS00034054g0003.1 Glycine rich RNA binding protein 15.6 3 
NbS00017754g0002.1 Glyoxylate_hydroxypyruvate reductase B 42.9 3 
giǀ38325815 Heat shock protein 70-3 (Nicotiana tabacum) 71 8 
NbS00016215g0013.1 Inorganic pyrophosphatase 50 3 
NbS00035212g0002.1 L ascorbate peroxidase 2 cytosolic 38.8 2 
giǀ32746733 
mRNA-binding protein precursor (Nicotiana 
tabacum) 
44.2 3 
NbS00028679g0001.1 NAD dependent epimerase_dehydratase 34.3 2 
NbS00022693g0009.1 Nitrite reductase 84.8 3 
NbS00003559g0006.1 Nucleoside diphosphate kinase 16.2 4 
NDK1_TOBAC 
Nucleoside diphosphate kinase 1 (Nicotiana 
tabacum) 
16.3 6 
NbS00017066g0003.1 Oxalate oxidase germin 171 21.6 2 
NbS00002520g0008.1 
Oxygen evolving enhancer protein 2, 
chloroplastic 
37.7 4 
NbS00010498g0007.1 Oxygen evolving enhancer protein 3 24.2 8 
NbS00022787g0008.1 Peroxiredoxin 30.2 4 
NbS00018854g0005.1 Phosphoenolpyruvate carboxylase 1 109.6 3 
NbS00020603g0012.1 Phosphoglucomutase, cytoplasmic 64.6 6 
NbS00001859g0006.1 Phosphoglycerate kinase 50.1 12 
giǀ2499497 
Phosphoglycerate kinase, chloroplastic 
(Nicotiana tabacum) 
50.1 10 
NbS00001361g0009.1 Phosphoglycolate phosphatase 40 5 
giǀ294440432 Plastidic aldolase (Nicotiana tabacum) 42.8 6 
giǀ194396261 Plastid transketolase (Nicotiana tabacum) 80     11 
NbS00011182g0007.1 Ribose 5 phosphate isomerase 29.8 2 
NbS00016026g0011.1 
Ribosome recycling factor, chloroplastic 
fragment 
32.6 2 
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Accession no. Protein name 
Size 
(kDa) 
Peptide 
found 
NbS00040945g0003.1 
RuBisCO large subunit-binding protein subunit 
alpha, chloroplastic 
62.3 16 
RBL_NICSY 
Ribulose bisphosphate carboxylase large chain 
(Nicotiana sylvestris) 
52.9 22 
NbS00037852g0006.1 
Ribulose bisphosphate carboxylase small chain 
8B, chloroplastic 
20.6 8 
NbS00011304g0015.1 S adenosyl L homocysteine hydrolase 48.7 2 
NbS00027670g0006.1 Serine hydroxymethyltransferase 59 7 
NbS00043086g0003.1 Sedoheptulose bisphosphatase 33.5 6 
NbS00019758g0008.1 Serine glyoxylate aminotransferase 43.9 3 
NbS00059057g0001.1 
Superoxide dismutase Fe, chloroplastic 
fragment 
28 3 
NbS00031996g0007.1 Thioredoxin 21.7 2 
NbS00007905g0010.1 Triosephosphate isomerase, chloroplastic 33.1 3 
PEG (precipitation) precipitate of N. tabacum 
giǀ4262869 RuBisCO large chain (Nicotiana tabacum) 52.9 18 
giǀ30013663 RuBisCO small chain (Nicotiana tabacum) 20.3 8 
Search database [NbS….: Nicotiana benthamiana database (Sol Genomics), giǀ….: NCBInr database 
(green plants), RBL_NICSY, PMGI_TOBAC, NDK1_TOBAC: SwissProt database] 
 
 
 
 
 
 
 
 
 
    
VII. Appendix                                                                                                               Page 108 
 
 
Institute for Molecular Biotechnology at the RWTH Aachen University 
PhD thesis 2015 by Zulfaquar Ahmad Arfi 
 
 Antiserum titer in individual bleeds following immunization with HCPs 
Table VII.2: Antiserum titer (section II.17.1) in individual bleeds of rabbits after immunization with 
NtHCPs and NtRdHCPs 
Bleed N. tabacum antiserum RuBisCO-depleted N. tabacum antiserum 
Bleed 1 1:160,000 1:192,000 
Bleed 2 1:384,000 1:256,000 
Bleed 3 1:160,000 1:320,000 
Bleed 4 1:256,000 1:256,000 
Bleed final 1:128,000 1:128,000 
Bleed pool 1:256,000 1:256,000 
 
Table VII.3: Antiserum titer (section II.17.1) in individual bleeds of rabbits after immunization with 
NbHCPs 
   Bleed N. benthamiana anti-HCP antiserum 
Bleed 1 1:8,000 
Bleed 2 1:32,000 
Bleed 3 1:32,000 
Bleed 4 1:32,000 
Bleed final 1:32,000 
Bleed pool 1:32,000 
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